Learn

Herb–Drug Interaction Register

What the published record actually says about four of these botanicals and five classes of prescription medicine — including the one case where it says something real.

Open the pathway atlas →

How to take a blend — 1/8 tsp of a 200:1 concentrate in coffee, juice, a smoothie or tea — with a little fat.

Who makes this, and why · Contact

Share 𝕏  X ●  Facebook ◉  Reddit ✈  WhatsApp ➤  Telegram ✉  Email 🔗  interstellarblends.com/learn/interactions.html

What this register is

Four botanicals that appear in these formulas — goji (Lycium barbarum), eleuthero (Eleutherococcus senticosus), albizia (Albizia julibrissin) and snow lotus (Saussurea involucrata) — searched against five classes of prescription medicine. Twenty cells. Each one carries a grade, the record it rests on, and the exposure that record was observed at.

Two cells hold human records and both are stated here in full. The other eighteen are graded C or lower, and most of them have no primary source at all. Both results are published, because a register that only printed the comfortable half would not be worth reading.

A grade here describes the evidence, never a person. Anyone taking a prescription medicine has a prescriber who holds their actual medication list, and that is the right place for a decision about it.

Goji — Lycium barbarum

Drug classWhat the record shows
AnticoagulantsB+ — four human case reports
Blood pressureNone — meta-analysis found no change
Diabetes drugsNone — no co-administration study found
SedativesNone — no human or animal record
Cardiac drugsNone — no record found

Eleuthero — Eleutherococcus senticosus

Drug classWhat the record shows
AnticoagulantsB+ — four reports, all confounded
Blood pressureNone — contraindication withdrawn
Diabetes drugsNone — no eleuthero co-administration study found
SedativesC — consumer databases disagree, neither sourced
Cardiac drugsC — one 1996 case, product unidentified

Albizia — Albizia julibrissin

Drug classWhat the record shows
AnticoagulantsNone
Blood pressureNone
Diabetes drugsNone
SedativesC — one mechanism excluded, sedation not
Cardiac drugsNone

Snow lotus — Saussurea involucrata

Drug classWhat the record shows
AnticoagulantsNone
Blood pressureNone
Diabetes drugsNone
SedativesC — a constituent binds; exposure unquantified
Cardiac drugsNone

A — human trial. B+ — human data, or animal evidence replicated by an independent laboratory. B — preclinical across three independent streams. C — exploratory. None — no record found, with the search stated below.

Goji and anticoagulants — the strongest human record here

Four published case reports describe a rise in INR when goji was taken alongside warfarin. Two are characterized as probable by their own authors; no published Naranjo score exists for any of them, and the first report states plainly that none was assigned. This is not softened and not buried.

Lam 2001: a 61-year-old woman drinking three to four glasses a day of concentrated goji tea for four days, INR rising from a 2–3 range to 4.1. Rivera 2012: a 71-year-old woman taking 60 mL a day of goji juice for four days, prothrombin time beyond 120 seconds. Zhang 2015: a 65-year-old man after 20 mL of goji wine in a single evening, INR 3.84.

Every one of those exposures was a high-extraction form — concentrated tea, juice, or an alcohol extract — at an estimated 6 to 18 grams of berries a day, taken daily. The proposed mechanism is inhibition of the liver enzyme CYP2C9, which is the enzyme that clears warfarin.

The measured detail that matters: inhibition depends on how the plant is extracted, not on how concentrated the extract is. Water extracts inhibit CYP2C9 below 30 percent, juice above 75 percent, and an 80 percent ethanol extract above 90 percent. The polyphenolic fraction is roughly 85 times more potent at this enzyme than the polysaccharide fraction — a ratio worked out from the two published figures rather than stated in the source. Every one of those concentrations is a laboratory concentration, orders of magnitude above anything swallowing produces, which is why this register rests the warning on the four human case reports and not on the enzyme work.

Goji appears in nine of the sixty-eight formulas. The largest single-serving exposure among them is Female Fertility, where goji is one of twenty-nine ingredients. Anyone taking warfarin or another anticoagulant should put that in front of their prescriber before adding any of them.

Eleuthero is the second B+ in the table and it is graded on record class alone. A 2023 pharmacovigilance analysis of 1,816 adverse-event reports found four involving eleuthero, three of them bleeding events. All three subjects were also taking an antidepressant together with aspirin, clopidogrel, ticagrelor or rivaroxaban. No dose was recorded, no causality score was assigned, and the mechanism was assumed rather than measured. A rat study of eleuthero with warfarin found no significant effect.

Albizia and sedatives — one mechanism excluded, the question still open

The circulating claim is that albizia adds to benzodiazepines because it is traditionally used for calm. One mechanism behind that claim has been measured and excluded. The effect itself has not, and an earlier version of this page said otherwise.

In a 2010 experiment, an ethanol extract of albizia was tested at the benzodiazepine binding site of the GABA-A receptor across concentrations from 0.001 to 10 mg/mL. It displaced between −20.7 and 16.5 percent. In the same assay and the same run, licorice displaced 97.7 percent and danshen 90.2 percent. The assay was working. Albizia does not act at that site.

That settles the mechanism and not the outcome. The same paper went on to give albizia to mice alongside a dose of pentobarbital too small to put them to sleep on its own. At 250 mg/kg — a dose with no hypnotic effect by itself — three of fifteen animals slept; at 500 mg/kg, six of fifteen; at 1,000 mg/kg, ten of fifteen. The authors also report that 250 mg/kg, inert alone, was significant in combination with diazepam. Albizia appears to reach the brain by a different route: it binds the 5-HT2C receptor, which a second independent study supports. A different route is not the same as no effect, and the binding result alone does not close this cell.

What does exist for albizia is rodent behavioral work, in three independent streams, at 200 to 1,000 mg/kg by mouth. Converted by body-surface-area scaling, the lowest effective animal dose corresponds to roughly 1.1 grams of extract for a 70-kilogram adult, and the highest to about 5.7 grams. The mechanism in that work is serotonergic, not GABAergic. Traditional use is not evidence of a drug interaction, and it is not recorded here as one.

For snow lotus, four of the five cells have no record in either direction. A quoted-phrase search of a 373-record corpus returned zero results for hypertension, diabetic or anticoagulant terms, and the apex pharmacology review of the species carries no interaction data and no safety section at all. The sedative cell is different, and the difference is a lesson about method. That search looked for drug-class words, which cannot find a mechanism that lives in a constituent. Published analyses of Saussurea involucrata report hispidulin among its flavonoids, and hispidulin is a documented positive allosteric modulator at the benzodiazepine site that crosses into the brain — the very mechanism excluded for albizia two paragraphs above. How much hispidulin this species carries has not been quantified in anything we opened, and no human data exist, so this is an open cell rather than a demonstrated interaction. It is graded C and not None, because None would be the wrong denominator.

Where the warnings come from

Three of the five classes have no primary source for any of the four botanicals. Following each warning back to its origin is part of the record.

Blood pressure and diabetes both trace to a single precautionary clause in one secondary textbook. The published evidence runs the other way. A meta-analysis of ten randomized controlled trials of goji recorded no change in blood pressure. A controlled trial of goji in 67 patients found its effect on glucose was smaller in people already taking antidiabetic medication, not larger — the opposite of the additive-hypoglycemia warning. A randomized crossover trial of eleuthero found it raised post-load glucose rather than lowering it.

The European Medicines Agency's monograph on eleuthero records interactions as “None reported,” and that wording is stable across two assessment rounds a decade apart. The agency also removed arterial hypertension as a contraindication between those rounds. A later review traced that contraindication to mid-1960s sources that had been misread, one recording systolic pressure falling by 12.4 mmHg and another being a study of radish-seed germination. We have not opened those sources ourselves, so we name the chain rather than vouch for it; a 2025 review of the species still describes the blood-pressure evidence as running in both directions.

The eleuthero and digoxin case is a single 1996 report. Serum digoxin rose; there was no toxicity and the electrocardiogram was unchanged. The level fell when the capsules were stopped and rose again when the patient resumed them, which is the strongest pattern a single case can show; an earlier version of this page left that out. The capsules were tested for digoxin and digitoxin and contained neither, but were never tested to confirm they contained eleuthero at all. Two explanations have been offered since and neither is settled. A 2025 review of the species states the implicated material was Periploca sepium, a different plant that does carry cardiac glycosides, citing a 1996 comment whose own title frames it as a possible mistaken identity rather than a finding. Separately, a series of laboratory papers from one group reports that eleuthero carries substances which read falsely high on one digoxin immunoassay and falsely low on another. Assay interference would produce the same stop-and-start pattern, so the rechallenge does not separate the two explanations. In the thirty years since, across six enumerating sources including a survey of 172 patients taking digoxin, no independent second case has been recorded.

The albizia sedative rating in consumer databases carries no references at all, and one widely redistributed monograph states plainly: “Interactions: None well documented.”

Concentration is not exposure

A 200:1 extract is more potent per milligram. It does not follow that a serving delivers more of the plant than a trial did, and the arithmetic is published here so it can be checked.

A 25-gram jar holds 75 servings, so a serving is 333 mg of finished concentrate. Trinity carries 74 ingredients, so an equal share is about 4.5 mg each. At 200:1 that is roughly 0.90 grams of raw-herb equivalent. In the nine formulas containing goji the figure ranges from 0.62 grams in Force Field, which has 108 ingredients, to 2.30 grams in Female Fertility, which has 29.

This is the same arithmetic the European Medicines Agency uses. Its eleuthero monograph accepts a dry aqueous extract at a 15–17:1 ratio, 90 to 180 mg, and states that as “corresponding to 0.5–4 g dried root.” Ratio multiplied by mass. On that basis a serving here sits at the low end of the agency's own accepted daily range, and below every human trial exposure that can be converted.

Two limits on that reasoning, stated rather than left out. The equal-share assumption is an assumption; a weighted formula moves the figure. And a ratio conversion estimates exposure, not constituent equivalence, because selective extraction can enrich particular compounds relative to the whole plant. Against the documented goji cases at 6 to 18 grams of berries daily, the margin is between roughly two and eight times, not a hundredfold.

What was searched, and what was not reached

Completeness is a fraction with a denominator. Here is the one this register was built on.

Four botanicals against six enumerating authorities gives 24 monograph cells: 16 fully resolved, 4 partial, 4 unresolved. Languages searched: English throughout, plus Chinese, Korean, Japanese and Russian. The Russian pass retrieved the official product label in full, which carries all five drug classes as formal label text with no evidence cited for any of them — a record of a warning, never of an observation.

Not reached, and named rather than omitted: the World Health Organization monographs, where all four cells remain unopened after three channels refused; the CNKI and Wanfang Chinese databases, which returned no reachable endpoint; the dedicated Health Canada eleuthero monograph, whose page errored; the Commission E text, whose presence was proven but whose wording was never opened; and the full text of the 1996 digoxin case report, which is cited here from its bibliographic record and two independent agreeing secondary sources rather than from the paper itself. No grade in this register rests on any of them.

One further limit: two widely cited consumer databases are not independent sources on goji. Both terminate on the same series of case reports, which makes them one stream and not two. They are counted once.

This register was compiled on 12 November 2026 and covers four botanicals of the 940 in this catalog in depth, chosen because they are the ones currently being asked about: for these four the primary sources were read and graded case by case. A second, wider pass — the systematic interaction sweep across all 940 ingredients — was run on 2026-11-14 against twelve published interaction reviews and is published in the Limits Register at /learn/limits.html; it flags 126 of those 940 across 61 of 68 blends. The two differ in kind: the sweep records that a published review names a botanical in a drug class, while this page records what the underlying papers actually say. So the absence of an entry on this page means these four were the ones examined closely, not that an ingredient is inert.

The systematic sweep — all 940 ingredients, 17 drug classes

The four botanicals above were read closely. This is the other pass: every one of the 940 ingredients in this catalog matched against twelve published interaction reviews, run on 2026-11-14. Matching was done three ways — by botanical binomial, by common name, and by the ingredient page slug — because a single method misses ingredients whose pages carry no binomial. 126 of 940 ingredients matched at least one drug class, and those 126 appear in 61 of 68 blends; 7 blends carry none of them.

What a row here is, and what it is not. A row states that a published review names that botanical in that drug class, and gives the evidence the review itself reports for it. It is not a measured interaction in one of these formulas. No blend here has been through a human drug-interaction trial, the sweep says nothing about the amount of any ingredient in a serving, and it cannot tell a reader how a particular jar will behave alongside a particular prescription. Some rows below rest on a single case report, some on animal data, some on a clinical pharmacokinetic study; the evidence column says which, in the review’s own terms, and it is not graded or summarized here.

The absence of an ingredient from every table below means it matched none of these twelve reviews. That is not evidence that it is inert.

The 17 class readings, over 12 distinct reviews

Drug classReview, and when it was retrievedListed / matched
Anticoagulants and antiplateletsRisks of Oral Anticoagulants: Interactions with Drugs and Medicinal Plants, Scientia Pharmaceutica 2025;93(3):35, mdpi.com/2218-0532/93/3/35
retrieved 2026-11-14
27 listed in the review, 33 matched here
Antidepressants, MAOIs and serotonergic drugsPharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22
retrieved 2026-11-14
11 listed in the review, 19 matched here
Antidiabetic drugsInteractions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications, Diabetol Metab Syndr 2017;9:59, doi:10.1186/s13098-017-0254-9
retrieved 2026-11-14
15 listed in the review, 25 matched here
Antihypertensives and blood-pressure drugsCardiovascular Effects of Herbal Products and Their Interaction with Antihypertensive Drugs - Comprehensive Review, PMC11203894
retrieved 2026-11-14
11 listed in the review, 23 matched here
CYP450 enzymes and P-glycoproteinInteractions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review, PMC13524159
retrieved 2026-11-14
32 listed in the review, 35 matched here
Cardiac drugs, arrhythmia and QT prolongationPharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22
retrieved 2026-11-14
15 listed in the review, 19 matched here
MSD Manual multi-class tableSome Possible Dietary Supplement-Medication Interactions, MSD Manual Professional Edition (Merck), msdmanuals.com
retrieved 2026-11-14
29 listed in the review, 42 matched here
Sedatives CNS depressants and benzodiazepinesCzigle et al. Pharmacokinetic and pharmacodynamic herb-drug interactions - part I. Herbal medicines of the central nervous system. PeerJ 2023;11:e16149. doi:10.7717/peerj.16149
retrieved 2026-11-14
11 listed in the review, 13 matched here
Thyroid medicationWiesner A, Gajewska D, Pasko P. Levothyroxine Interactions with Food and Dietary Supplements - A Systematic Review. Pharmaceuticals 2021;14(3):206. doi:10.3390/ph14030206
retrieved 2026-11-14
16 listed in the review, 2 matched here
ImmunosuppressantsMiedziaszczyk M, Bajon A, Jakielska E, Primke M, Sikora J, Skowronska D, Idasiak-Piechocka I. Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food. Pharmaceutics 2022;14(10):2154. doi:10.3390/pharmaceutics14102154
retrieved 2026-11-14
13 listed in the review, 16 matched here
Statins and lipid-lowering drugsPrieto-Garcia JM, Graham L, Alkhabbaz O, Mazzari ALDA. Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review. Plants (Basel) 2023;12(3):623. doi:10.3390/plants12030623
retrieved 2026-11-14
25 listed in the review, 16 matched here
Digoxin and cardiac glycosidesZhuang W, He T, Jia B-B, Wang Z-Z, Zhang L, Dong X-Z, Xi S-Y. Interaction between Chinese medicine and digoxin: Clinical and research update. Front Pharmacol 2023;14:1040778. doi:10.3389/fphar.2023.1040778
retrieved 2026-11-14
50 listed in the review, 44 matched here
Chemotherapy and oncology agentsFasinu PS, Rapp GK. Herbal Interaction With Chemotherapeutic Drugs - A Focus on Clinically Significant Findings. Front Oncol 2019;9:1356. doi:10.3389/fonc.2019.01356
retrieved 2026-11-14
19 listed in the review, 28 matched here
Anticoagulants and antiplatelets (Table 3, completed retrieval)Risks of Oral Anticoagulants: Interactions with Drugs and Medicinal Plants, Scientia Pharmaceutica 2025;93(3):35, mdpi.com/2218-0532/93/3/35 - Table 3 read in full on a completion pass, characters 100,000-128,599
retrieved 2026-11-14
26 listed in the review, 31 matched here
Serotonergic drugs (Table 1, completed retrieval)Pharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22 - Table 1 read on a completion pass at characters 200,000-241,705
retrieved 2026-11-14
11 listed in the review, 17 matched here
Cardiac arrhythmia and QT (Table 2, completed retrieval)Pharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22 - Table 2 read on a completion pass at characters 200,000-241,705
retrieved 2026-11-14
17 listed in the review, 18 matched here
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review, Journal of the Chinese Medical Association 2026;89(8):578-592, doi 10.1097/JCMA.0000000000001404, PMC13524159 - all seven tables read on a completion pass. Tables 1 and 2 carry no botanicals (CYP families and CYP polymorphisms). Cell prose in this pass is close paraphrase of the source, not verbatim quotation; table captions, column headers, row counts, plant names, isoforms, directions and the figures shown in quotation marks are read from the page
retrieved 2026-11-14
31 listed in the review, 27 matched here

"Listed" is how many botanicals the review names. "Matched here" is how many ingredient pages in this catalog those names reach, which is the larger number wherever one botanical appears in this catalog as several ingredients — a whole herb and its named constituents, for instance.

Anticoagulants and antiplatelets — 35 matched

Source: Risks of Oral Anticoagulants: Interactions with Drugs and Medicinal Plants, Scientia Pharmaceutica 2025;93(3):35, mdpi.com/2218-0532/93/3/35, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumlimited case reports, plausible
Aloe verableeding risk described
Anthocyanins Vaccinium myrtillus + Ribes nigrumtheoretical, platelet aggregation
Bilberry Vaccinium myrtillustheoretical, platelet aggregation
Cranberry Vaccinium macrocarponmechanism described
Dong quai Angelica sinensisnot stated
EGCG Camellia sinensisvitamin K content
EGCG and EGC (green tea) Camellia sinensisvitamin K content
Garlic Allium sativumlimited case reports, plausible
Ginger Zingiber officinalemechanism described
Ginkgo bilobalimited data
Glabridin Glycyrrhiza glabranot stated
Glycyrrhizin (Licorice) Glycyrrhiza glabranot stated
Goji berry Lycium barbarumwith high intake
Gotu kola Centella asiaticanot stated
Green tea polyphenols Camellia sinensisvitamin K content
Harpagophytum (Devil's Claw) Harpagophytum procumbensnot stated
Isoliquiritigenin Glycyrrhiza glabranot stated
Licorice Glycyrrhiza glabranot stated
Matcha Camellia sinensisvitamin K content
Milk Thistle Silybum marianumnot stated
Myrrh Commiphora myrrhasingle case report
Panax quinquefolius (American ginseng) Panax quinquefoliusunclear effects on warfarin efficacy
Polyenylphosphatidylcholine (PPC) Glycine max phospholipid fractionnot stated
Purple coneflower Echinacea purpureahealthy-subject study, no pharmacodynamic effect
Red clover Trifolium pratensecited case report of coagulation disorder
Red sage Salvia miltiorrhizamechanism described
Saw palmetto Serenoa repenslimited evidence, unclear
Silibinin Silybum marianumnot stated
Soy peptide fraction (hydrolyzed soy) Glycine maxnot stated
Soybean Glycine maxnot stated
St. John's wort Hypericum perforatummay reduce DOAC effectiveness
Tea Camellia sinensisvitamin K content
Turmeric Curcuma longanot stated
Valerian Valeriana officinalisDOAC caution only

Antidepressants, MAOIs and serotonergic drugs — 20 matched

Source: Pharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22, retrieved 2026-11-14.

IngredientWhat the review reports
5-HTPcase reports; mechanistic plausibility
Ashwagandha Withania somniferaone recent case report (escitalopram); CYP3A4/2D6 inhibition
Asian ginseng Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Berberinepreclinical MAO-A and CYP inhibition; no clinical cases
Cimicifuga racemosa Actaea racemosaone 2024 case report; 5-HT receptor activity
Curcumin Curcuma longa L.MAO-A inhibition by curcumin; case report; FAERS signal (30 reports)
Dammarane sapogenins (from oriental ginseng) Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Ginkgo bilobapreclinical MAO inhibition; case report of hypomania; 4 FAERS
Ginsenoside Rb2 Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Ginsenoside Rc Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Ginsenoside Rg1 Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Ginsenoside Rg3 Panax ginsengcase reports + mechanistic; no pharmacovigilance data
ginsenoside Rh Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Golden root Rhodiola roseaone case report (paroxetine); CYP inhibition; no FAERS
Goldenseal Hydrastis canadensisberberine-rich; theoretical
Panaxotriol Panax ginsengcase reports + mechanistic; no pharmacovigilance data
Salidroside (Rhodiola) Rhodiola roseaone case report (paroxetine); CYP inhibition; no FAERS
St. John's wort Hypericum perforatumcase series + FAERS signal (34 cases)
Turmeric Curcuma longaMAO-A inhibition by curcumin; case report; FAERS signal (30 reports)
Withanolides (Ashwagandha) Withania somniferaone recent case report (escitalopram); CYP3A4/2D6 inhibition

Antidiabetic drugs — 26 matched

Source: Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications, Diabetol Metab Syndr 2017;9:59, doi:10.1186/s13098-017-0254-9, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumincreased metformin Cmax and AUC in rats; potentiated effect clinically
Aloe veraadditive with glibenclamide, pioglitazone, repaglinide
Asian ginseng Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Astragalus Astragalus membranaceusaltered pioglitazone pharmacokinetics in humans
Baicalein Scutellaria baicalensisenhanced metformin antidiabetic action in rats
Baicalin Scutellaria baicalensis Georgienhanced metformin antidiabetic action in rats
Baikal skullcap Scutellaria baicalensisenhanced metformin antidiabetic action in rats
Bitter melon Momordica charantiaadditive with metformin or glibenclamide, clinical and rat
Dammarane sapogenins (from oriental ginseng) Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Fenugreek Trigonella foenum-graecumgreater glucose reduction with metformin in animal models
Garlic Allium sativumincreased metformin Cmax and AUC in rats; potentiated effect clinically
Ginger Zingiber officinaleenhanced glucose lowering with glibenclamide in rats
Ginsenoside Rb2 Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Ginsenoside Rc Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Ginsenoside Rg1 Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Ginsenoside Rg3 Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
ginsenoside Rh Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Green chiretta Andrographis paniculatainhibits CYP2C19 which metabolises sulfonylureas and glinides
Gymnema sylvestrereduced metformin bioavailability; mixed results
Oleuropein Olea europaeareduced HbA1c and fasting insulin in T2D trial
Olive leaf Olea europaeareduced HbA1c and fasting insulin in T2D trial
Panax quinquefolius (American ginseng) Panax quinquefoliuscompound K additive with metformin in mice
Panaxotriol Panax ginsengcase report of hypoglycaemia with metformin + repaglinide
Prickly pear Opuntia ficus-indicahypoglycaemic reaction with glipizide and metformin in a patient
St. John's wort Hypericum perforatumdecreased renal clearance of metformin
Wogonin Scutellaria baicalensisenhanced metformin antidiabetic action in rats

Antihypertensives and blood-pressure drugs — 23 matched

Source: Cardiovascular Effects of Herbal Products and Their Interaction with Antihypertensive Drugs - Comprehensive Review, PMC11203894, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumnifedipine higher exposure; propranolol higher bioavailability (rats)
Aloe verano adverse interaction expected; laxative action may reduce absorption
Asian ginseng Panax ginsengfurosemide resistance reported; amlodipine delayed peak
Berberinelosartan and irbesartan higher levels
Celery Apium graveolensapigenin may inhibit CYP3A4 (mechanistic)
Dammarane sapogenins (from oriental ginseng) Panax ginsengfurosemide resistance reported; amlodipine delayed peak
EGCG Camellia sinensislisinopril and nadolol lower levels; amlodipine higher via CYP3A inhibition (rats)
EGCG and EGC (green tea) Camellia sinensislisinopril and nadolol lower levels; amlodipine higher via CYP3A inhibition (rats)
Garlic Allium sativumnifedipine higher exposure; propranolol higher bioavailability (rats)
Ginger Zingiber officinaleamlodipine and losartan enhanced; clopidogrel CYP2C19 inhibition in vitro
Ginkgo bilobalosartan higher levels, lower EXP3174; talinolol higher
Ginsenoside Rb2 Panax ginsengfurosemide resistance reported; amlodipine delayed peak
Ginsenoside Rc Panax ginsengfurosemide resistance reported; amlodipine delayed peak
Ginsenoside Rg1 Panax ginsengfurosemide resistance reported; amlodipine delayed peak
Ginsenoside Rg3 Panax ginsengfurosemide resistance reported; amlodipine delayed peak
ginsenoside Rh Panax ginsengfurosemide resistance reported; amlodipine delayed peak
Green tea polyphenols Camellia sinensislisinopril and nadolol lower levels; amlodipine higher via CYP3A inhibition (rats)
Matcha Camellia sinensislisinopril and nadolol lower levels; amlodipine higher via CYP3A inhibition (rats)
Panax quinquefolius (American ginseng) Panax quinquefoliusmixed BP effects
Panaxotriol Panax ginsengfurosemide resistance reported; amlodipine delayed peak
Tea Camellia sinensislisinopril and nadolol lower levels; amlodipine higher via CYP3A inhibition (rats)
Thymoquinone Nigella sativalosartan enhanced effect and higher levels; dose adjustment may be needed
Wild thyme Thymus serpyllumgreater diastolic reduction when combined

CYP450 enzymes and P-glycoprotein — 37 matched

Source: Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review, PMC13524159, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumgarlic oil inhibits CYP2E1
Asian ginseng Panax ginsenginduces CYP3A4 (clinical midazolam study)
Astragalus Astragalus membranaceusCYP3A4 induction (low evidence); weak CYP2C9/3A4 inhibition in vitro
Baicalein Scutellaria baicalensisinhibits CYP2C9; induces CYP2E1
Baicalin Scutellaria baicalensis Georgiinhibits CYP2C9; induces CYP2E1
Baikal skullcap Scutellaria baicalensisinhibits CYP2C9; induces CYP2E1
Chinese magnolia vine Schisandra chinensisinhibits CYP3A
Common barberry Berberis vulgarisberberine inhibits CYP2D6, CYP3A4
Cranberry Vaccinium macrocarponinhibits CYP2C9
Curcumin Curcuma longa L.inhibits CYP3A/1A1/1A2/2B1 via curcumin
Dammarane sapogenins (from oriental ginseng) Panax ginsenginduces CYP3A4 (clinical midazolam study)
Deoxyschizandrin Schisandra chinensisinhibits CYP3A
Dong quai Angelica sinensismixed inhibition/induction CYP1A2/2D6/2C9/2E1/3A4
Epimedium (Horny Goat Weed) Epimedium koreanumbroad inhibition CYP3A4/2C9/2C19
Garlic Allium sativumgarlic oil inhibits CYP2E1
German chamomile Matricaria chamomillainduces murine CYP3A11/1A2 (not human CYP3A4)
Ginkgo bilobainduces CYP2C19, CYP3A4
Ginsenoside Rb2 Panax ginsenginduces CYP3A4 (clinical midazolam study)
Ginsenoside Rc Panax ginsenginduces CYP3A4 (clinical midazolam study)
Ginsenoside Rg1 Panax ginsenginduces CYP3A4 (clinical midazolam study)
Ginsenoside Rg3 Panax ginsenginduces CYP3A4 (clinical midazolam study)
ginsenoside Rh Panax ginsenginduces CYP3A4 (clinical midazolam study)
Goji berry Lycium barbaruminhibits CYP2C9, CYP3A4, CYP1A2
Green chiretta Andrographis paniculatainhibits CYP3A4, CYP2B, CYP2C
He Shou Wu Polygonum multifloruminhibits CYP1A2/2E1/3A4 (mainly in vitro)
Milk Thistle Silybum marianummildly inhibits CYP3A4
Myrrh Commiphora myrrhainduces CYP2C9 via PXR
Panaxotriol Panax ginsenginduces CYP3A4 (clinical midazolam study)
Pomegranate Punica granatuminhibits CYP3A4 and CYP2C9
Punicalagin (from pomegranate extract) Punica granatuminhibits CYP3A4 and CYP2C9
Red sage Salvia miltiorrhizainduces CYP1A2/2C9/3A4; inhibits CYP1A2/2C9/2C19
Rheum palmatum (rhein, a hydroxyanthraquinone) Rheum palmatum (rhein, a hydroxyanthraquinone)induces CYP2D6
Schisandrin B Schisandra chinensisinhibits CYP3A
Silibinin Silybum marianummildly inhibits CYP3A4
St. John's wort Hypericum perforatumstrongly induces CYP3A4/2C9/2E1
Turmeric Curcuma longainhibits CYP3A/1A1/1A2/2B1 via curcumin
Wogonin Scutellaria baicalensisinhibits CYP2C9; induces CYP2E1

Cardiac drugs, arrhythmia and QT prolongation — 19 matched

Source: Pharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22, retrieved 2026-11-14.

IngredientWhat the review reports
Aloe verahypokalemia route; one heart-failure report
Asian ginseng Panax ginsengin vivo hERG; one long QT/torsade case report
Berberinein vitro hERG and CYP3A4; one sinus bradycardia case
Bitter Orange Citrus aurantiumcase reports and mechanistic
Dammarane sapogenins (from oriental ginseng) Panax ginsengin vivo hERG; one long QT/torsade case report
Evodia (Wu Zhu Yu) Evodia rutaecarpaexperimental hERG inhibition
Ginsenoside Rb2 Panax ginsengin vivo hERG; one long QT/torsade case report
Ginsenoside Rc Panax ginsengin vivo hERG; one long QT/torsade case report
Ginsenoside Rg1 Panax ginsengin vivo hERG; one long QT/torsade case report
Ginsenoside Rg3 Panax ginsengin vivo hERG; one long QT/torsade case report
ginsenoside Rh Panax ginsengin vivo hERG; one long QT/torsade case report
Glabridin Glycyrrhiza glabramultiple case reports; FAERS 31 hypokalemia reports
Glycyrrhizin (Licorice) Glycyrrhiza glabramultiple case reports; FAERS 31 hypokalemia reports
Guarana Paullinia cupanacaffeine-containing; 37 FAERS arrhythmia cases (class)
Isoliquiritigenin Glycyrrhiza glabramultiple case reports; FAERS 31 hypokalemia reports
Licorice Glycyrrhiza glabramultiple case reports; FAERS 31 hypokalemia reports
Panaxotriol Panax ginsengin vivo hERG; one long QT/torsade case report
Yerba mate Ilex paraguariensiscaffeine-containing; class signal
Yohimbine Pausinystalia johimbeisolated case reports

MSD Manual multi-class table — 42 matched

Source: Some Possible Dietary Supplement-Medication Interactions, MSD Manual Professional Edition (Merck), msdmanuals.com, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumantihypertensives; antiplatelets; isoniazid; protease inhibitors; warfarin; oral tacrolimus (liver injury)
Ashwagandha Withania somniferathyroid hormones (raises levels); antihyperglycemics; antihypertensives; immunosuppressants (cyclosporine, tacrolimus, corticosteroids); sedatives
Asian ginseng Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
Astragalus Astragalus membranaceusimmunosuppressants (reduces effectiveness); lithium (reduces excretion)
Bacopa monnierianticholinergics and cholinergic drugs; thyroid hormones (raises levels); CYP450-metabolized drugs incl. warfarin, calcium channel blockers, antiseizure drugs
Cat's claw Uncaria tomentosaNCCIH: anticoagulant/antiplatelet, antihypertensives, calcium channel blockers, CYP3A4 substrates, immunosuppressants
Coenzyme Q10reduces warfarin response; adds to antihypertensives; interferes with chemotherapy
Cranberry Vaccinium macrocarponNCCIH: warfarin, conflicting evidence
Dammarane sapogenins (from oriental ginseng) Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
EGCG Camellia sinensisatorvastatin (reduces levels); nadolol; warfarin (reduces efficacy)
EGCG and EGC (green tea) Camellia sinensisatorvastatin (reduces levels); nadolol; warfarin (reduces efficacy)
Feverfew Tanacetum partheniumergotamine antimigraine drugs; antiplatelets; NSAIDs; warfarin
Ganoderma lucidumanticoagulants and antiplatelets; antihypertensives (hypotension); antihyperglycemics
Garlic Allium sativumantihypertensives; antiplatelets; isoniazid; protease inhibitors; warfarin; oral tacrolimus (liver injury)
German chamomile Matricaria chamomillabarbiturates and sedatives; iron absorption; warfarin; estrogenic drugs incl. tamoxifen; cyclosporine
Ginger Zingiber officinaleantiplatelets; warfarin
Ginkgo bilobaphenytoin; antidepressants (serotonin syndrome); MAOIs; NSAIDs; warfarin
Ginsenoside Rb2 Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
Ginsenoside Rc Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
Ginsenoside Rg1 Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
Ginsenoside Rg3 Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
ginsenoside Rh Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
Glabridin Glycyrrhiza glabraantihypertensives; paclitaxel and cisplatin; corticosteroids; digoxin (hypokalemia); diuretics; MAOIs; warfarin
Glycyrrhizin (Licorice) Glycyrrhiza glabraantihypertensives; paclitaxel and cisplatin; corticosteroids; digoxin (hypokalemia); diuretics; MAOIs; warfarin
Golden root Rhodiola roseaantidepressants (rapid heart rate); warfarin (raises levels); anti-inflammatories; immunosuppressants (reduces effectiveness); antihyperglycemics; antihypertensives
Goldenseal Hydrastis canadensisantihypertensives; antihyperglycemics; warfarin and heparin; metformin levels fell ~25% in an NCCIH-funded study
Green tea polyphenols Camellia sinensisatorvastatin (reduces levels); nadolol; warfarin (reduces efficacy)
Holy Basil Ocimum tenuiflorumthyroid hormones (reduces efficacy); anticoagulants and antiplatelets
Isoliquiritigenin Glycyrrhiza glabraantihypertensives; paclitaxel and cisplatin; corticosteroids; digoxin (hypokalemia); diuretics; MAOIs; warfarin
Licorice Glycyrrhiza glabraantihypertensives; paclitaxel and cisplatin; corticosteroids; digoxin (hypokalemia); diuretics; MAOIs; warfarin
Matcha Camellia sinensisatorvastatin (reduces levels); nadolol; warfarin (reduces efficacy)
Melatoninwarfarin bleeding risk; antiseizure medications (reduces effectiveness); benzodiazepines (increases sedation)
Milk Thistle Silybum marianumantihyperglycemics (hypoglycemia); protease inhibitors; sirolimus; warfarin
Panaxotriol Panax ginsengglipizide (hypoglycemia); aspirin/NSAIDs; corticosteroids; digoxin (raises levels); estrogens; MAOIs; opioids; warfarin
Salidroside (Rhodiola) Rhodiola roseaantidepressants (rapid heart rate); warfarin (raises levels); anti-inflammatories; immunosuppressants (reduces effectiveness); antihyperglycemics; antihypertensives
Saw palmetto Serenoa repensantiplatelets and warfarin; estrogens and oral contraceptives
Silibinin Silybum marianumantihyperglycemics (hypoglycemia); protease inhibitors; sirolimus; warfarin
St. John's wort Hypericum perforatumbenzodiazepines; cyclosporine and tacrolimus (transplant rejection); digoxin; iron; MAOIs (hypertensive emergency); ketamine; NNRTIs; oral contraceptives; opioids; phenobarbital; photosensitizers; protease inhibitors; SSRIs; statins; TCAs; warfarin and DOACs
Tea Camellia sinensisatorvastatin (reduces levels); nadolol; warfarin (reduces efficacy)
Valerian Valeriana officinalisbarbiturates and benzodiazepines (intensifies sedation)
Withanolides (Ashwagandha) Withania somniferathyroid hormones (raises levels); antihyperglycemics; antihypertensives; immunosuppressants (cyclosporine, tacrolimus, corticosteroids); sedatives
Zinccephalexin, tetracyclines, quinolones (reduces absorption); cisplatin; penicillamine; dolutegravir

Sedatives CNS depressants and benzodiazepines — 13 matched

Source: Czigle et al. Pharmacokinetic and pharmacodynamic herb-drug interactions - part I. Herbal medicines of the central nervous system. PeerJ 2023;11:e16149. doi:10.7717/peerj.16149, retrieved 2026-11-14.

IngredientWhat the review reports
Cocoa flavanols Theobroma cacaoCaffeine group row: reduced plasma level and anxiolytic effect; reduced hypnotic effect
EGCG Camellia sinensisCaffeine group row: reduced plasma level and anxiolytic effect (alprazolam, diazepam); reduced hypnotic effect (pentobarbital, triazolam, zolpidem, zopiclone)
EGCG and EGC (green tea) Camellia sinensisCaffeine group row: reduced plasma level and anxiolytic effect (alprazolam, diazepam); reduced hypnotic effect (pentobarbital, triazolam, zolpidem, zopiclone)
Green tea polyphenols Camellia sinensisCaffeine group row: reduced plasma level and anxiolytic effect (alprazolam, diazepam); reduced hypnotic effect (pentobarbital, triazolam, zolpidem, zopiclone)
Guarana Paullinia cupanaCaffeine group row: reduced plasma level and anxiolytic effect; reduced hypnotic effect
Hops Humulus lupulusAdditive effect, increased adverse reactions with diazepam and phenobarbital; humulone a positive allosteric modulator of GABA-A; mainly experimental evidence
Humulone Humulus lupulusAdditive effect, increased adverse reactions with diazepam and phenobarbital; humulone a positive allosteric modulator of GABA-A; mainly experimental evidence
Matcha Camellia sinensisCaffeine group row: reduced plasma level and anxiolytic effect (alprazolam, diazepam); reduced hypnotic effect (pentobarbital, triazolam, zolpidem, zopiclone)
St. John's wort Hypericum perforatumReduced anxiolytic effect (alprazolam, diazepam) and hypnotic effect (midazolam) via CYP2C19/3A4; reduced anticonvulsive effect of barbiturates
Tea Camellia sinensisCaffeine group row: reduced plasma level and anxiolytic effect (alprazolam, diazepam); reduced hypnotic effect (pentobarbital, triazolam, zolpidem, zopiclone)
Valerian Valeriana officinalisAdditive effect with propofol/thiopental, barbiturates, clonazepam; alprazolam plasma level up 19%; do not combine
Xanthohumol Humulus lupulusAdditive effect, increased adverse reactions with diazepam and phenobarbital; humulone a positive allosteric modulator of GABA-A; mainly experimental evidence
Yerba mate Ilex paraguariensisCaffeine group row: reduced plasma level and anxiolytic effect; reduced hypnotic effect

Thyroid medication — 2 matched

Source: Wiesner A, Gajewska D, Pasko P. Levothyroxine Interactions with Food and Dietary Supplements - A Systematic Review. Pharmaceuticals 2021;14(3):206. doi:10.3390/ph14030206, retrieved 2026-11-14.

IngredientWhat the review reports
Papaya Carica papayaTwo patients, TSH rose to 25 mU/L and from 0.8 to 15 mU/L; papain reduces gastric acid up to 48 hours; mechanism recorded as unknown
Tea Camellia sinensisHabitual breakfasts in a 77-patient RCT included tea with no significant difference; the review has no tea row and gives no tea recommendation

Immunosuppressants — 16 matched

Source: Miedziaszczyk M, Bajon A, Jakielska E, Primke M, Sikora J, Skowronska D, Idasiak-Piechocka I. Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food. Pharmaceutics 2022;14(10):2154. doi:10.3390/pharmaceutics14102154, retrieved 2026-11-14.

IngredientWhat the review reports
Asian ginseng Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
Cranberry Vaccinium macrocarponCase report of a DECREASE in tacrolimus serum levels in a renal transplant patient; recorded as inconclusive
Dammarane sapogenins (from oriental ginseng) Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
Ginger Zingiber officinaleIncreased tacrolimus AUC in rats; elevation of serum level recorded with no mechanism given
Ginsenoside Rb2 Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
Ginsenoside Rc Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
Ginsenoside Rg1 Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
Ginsenoside Rg3 Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
ginsenoside Rh Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
GrapefruitTwo-fold growth of blood tacrolimus levels; bergamottin and 6',7'-dihydroxybergamottin inhibit intestinal CYP3A4 and P-glycoprotein
Panaxotriol Panax ginsengEffect inconclusive, risk described as rather low; ginsenosides poorly inhibit CYP2D6 and P-glycoprotein
Pomegranate Punica granatumRoughly two-fold elevation after one to two juice-concentrate popsicles daily; quercetin noted as a CYP3A4 inhibitor, precise mechanism unknown
Pomelo Citrus maximaRaised tacrolimus after a single 100 g intake; rat juice and peel extract raised AUC and Cmax; one study contradicts the P-glycoprotein role
Purple coneflower Echinacea purpureaReduced clearance of CYP1A2 substrates, selectively modulates CYP3A; no tacrolimus numbers given
St. John's wort Hypericum perforatumBioavailability fell more than 50%; 600 mg/day for 14 days in renal transplant patients cut AUC 57.8%, with rejection risk; hyperforin induces CYP3A4 and P-glycoprotein via PXR
Turmeric Curcuma longaIncreased AUC in rats; a patient eating more than 15 spoons daily had a three-fold increase with acute nephrotoxicity

Statins and lipid-lowering drugs — 17 matched

Source: Prieto-Garcia JM, Graham L, Alkhabbaz O, Mazzari ALDA. Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review. Plants (Basel) 2023;12(3):623. doi:10.3390/plants12030623, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumCYP2C9 induction and inhibition (fluvastatin, rosuvastatin); CYP3A4/3A5 inhibition (atorvastatin, simvastatin, fluvastatin); preclinical
Bitter melon Momordica charantiaCYP3A4 inhibition affecting atorvastatin, fluvastatin, simvastatin; preclinical
Cat's claw Uncaria tomentosaCYP3A4 inhibition affecting atorvastatin, fluvastatin, simvastatin; preclinical
Curcumin Curcuma longa L.CYP3A4 first-pass inhibition (atorvastatin, fluvastatin, simvastatin); P-glycoprotein inhibition (atorvastatin); preclinical
Fennel Foeniculum vulgareCYP3A4 inhibition affecting atorvastatin, fluvastatin, simvastatin; preclinical
Gale of the wind Phyllanthus amarusCYP3A4 and CYP3A5 inhibition affecting statins; preclinical
Garlic Allium sativumCYP2C9 induction and inhibition (fluvastatin, rosuvastatin); CYP3A4/3A5 inhibition (atorvastatin, simvastatin, fluvastatin); preclinical
German chamomile Matricaria chamomillaCYP3A4 inhibition affecting atorvastatin, fluvastatin, simvastatin; preclinical
Ginger Zingiber officinaleCYP2C9 inhibition (fluvastatin, rosuvastatin) and CYP3A4 first-pass effect (atorvastatin, fluvastatin, simvastatin); preclinical
Guava Psidium guajavaNamed among herbs with no effect on CYPs that may not interact significantly with statins
Harpagophytum (Devil's Claw) Harpagophytum procumbensCYP2C9 no effect or inhibition affecting fluvastatin and rosuvastatin; preclinical
Peppermint Mentha piperitaCYP2C9 inhibition (fluvastatin, rosuvastatin) and CYP3A4 inhibition (atorvastatin, fluvastatin, simvastatin); preclinical
Pomegranate Punica granatumCYP2C9 and CYP3A4/3A5 inhibition affecting statins; preclinical
Punicalagin (from pomegranate extract) Punica granatumCYP2C9 and CYP3A4/3A5 inhibition affecting statins; preclinical
Red clover Trifolium pratenseCYP2C9 and CYP3A4 inhibition affecting statins; preclinical
Turmeric Curcuma longaCYP3A4 first-pass inhibition (atorvastatin, fluvastatin, simvastatin); P-glycoprotein inhibition (atorvastatin); preclinical
Yarrow Achillea millefoliumP-glycoprotein inhibition affecting atorvastatin; preclinical

Digoxin and cardiac glycosides — 44 matched

Source: Zhuang W, He T, Jia B-B, Wang Z-Z, Zhang L, Dong X-Z, Xi S-Y. Interaction between Chinese medicine and digoxin: Clinical and research update. Front Pharmacol 2023;14:1040778. doi:10.3389/fphar.2023.1040778, retrieved 2026-11-14.

IngredientWhat the review reports
Asian ginseng Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Bitter Orange Citrus aurantiumAcidic herb list: lowers digoxin bioavailability through gastric pH
Cherokee rose Rosa laevigataAcidic herb list: lowers digoxin bioavailability through gastric pH
Chinese magnolia vine Schisandra chinensisAcidic herb list: bioavailability decreased, contradicted by Wuzhi Tablet data in the same review
Chinese peony Paeonia lactifloraAcidic herb list: bioavailability decreased, contradicted elsewhere in the same review
Chinese rhubarb Rheum officinaleAcidic herb list: lowers digoxin bioavailability through gastric pH
Dammarane sapogenins (from oriental ginseng) Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Dandelion Taraxacum erythrospermumAcidic herb list: lowers digoxin bioavailability through gastric pH
Deoxyschizandrin Schisandra chinensisAcidic herb list: bioavailability decreased, contradicted by Wuzhi Tablet data in the same review
Dong quai Angelica sinensisAntiarrhythmic; the review says it can resist digoxin-induced arrhythmia, mechanism not clear
Dwarf lilyturf Ophiopogon japonicusNamed only as a Shenmai injection ingredient; the review gives no separate evidence
EGCG Camellia sinensisIn vitro P-glycoprotein inhibition; clinical study AUC fell from 8.20 to 5.44 ng*h/mL and Cmax from 2.47 to 1.76 ng/mL
EGCG and EGC (green tea) Camellia sinensisIn vitro P-glycoprotein inhibition; clinical study AUC fell from 8.20 to 5.44 ng*h/mL and Cmax from 2.47 to 1.76 ng/mL
Ginsenoside Rb2 Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Ginsenoside Rc Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Ginsenoside Rg1 Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Ginsenoside Rg3 Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
ginsenoside Rh Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Glabridin Glycyrrhiza glabraClinical report: mineralocorticoid-like effect, hypokalemia, increased digoxin sensitivity
Glossy privet Ligustrum lucidumAcidic herb list: lowers digoxin bioavailability through gastric pH
Glycyrrhizin (Licorice) Glycyrrhiza glabraClinical report: mineralocorticoid-like effect, hypokalemia, increased digoxin sensitivity
Green tea polyphenols Camellia sinensisIn vitro P-glycoprotein inhibition; clinical study AUC fell from 8.20 to 5.44 ng*h/mL and Cmax from 2.47 to 1.76 ng/mL
Hairy agrimony Agrimonia pilosaAcidic herb list: lowers digoxin bioavailability through gastric pH
Hawthorn Fruit Crataegus pinnatifidaAcidic herb list: bioavailability decreased; also reported to antagonize digoxin-induced arrhythmia
Isoliquiritigenin Glycyrrhiza glabraClinical report: mineralocorticoid-like effect, hypokalemia, increased digoxin sensitivity
Japanese apricotAcidic herb list: lowers digoxin bioavailability through gastric pH
Japanese cornel Cornus officinalisAcidic herb list: lowers digoxin bioavailability through gastric pH
Japanese honeysuckle Lonicera japonicaAcidic herb list: lowers digoxin bioavailability through gastric pH
Jujube Ziziphus jujubaAcidic herb list: lowers digoxin bioavailability through gastric pH
Licorice Glycyrrhiza glabraClinical report: mineralocorticoid-like effect, hypokalemia, increased digoxin sensitivity
Ligusticum / Chuanxiong (Chuan Xiong) Conioselinum anthriscoidesIn vitro Caco-2: plasma digoxin concentration increased
Matcha Camellia sinensisIn vitro P-glycoprotein inhibition; clinical study AUC fell from 8.20 to 5.44 ng*h/mL and Cmax from 2.47 to 1.76 ng/mL
Milk Thistle Silybum marianumRetrospective review: induces P-glycoprotein mRNA and may reduce bioavailability, while a human study found no significant change
Paeoniflorin Paeonia lactifloraAcidic herb list: bioavailability decreased, contradicted elsewhere in the same review
Panaxotriol Panax ginsengIn vitro: inhibits P-glycoprotein transport and competes for binding sites, plasma digoxin increased; human reports conflict
Papaya Carica papayaRat and in vitro: digoxin AUC increased; shares a common name with Chinese quince in this source
Purple nutsedge Cyperus rotundusRat: aqueous extract upregulates intestinal P-glycoprotein; the review states the effect on digoxin is not clear
Red sage Salvia miltiorrhizaContains cardiac glycosides with a cumulative effect; the review states the position is not clear
Schisandrin B Schisandra chinensisAcidic herb list: bioavailability decreased, contradicted by Wuzhi Tablet data in the same review
Silibinin Silybum marianumRetrospective review: induces P-glycoprotein mRNA and may reduce bioavailability, while a human study found no significant change
St. John's wort Hypericum perforatumHuman: 0.5 to 1 g/day of traditional products showed no significant interaction, while a high-dose extract reduced AUC 25% and plasma 36%
Sweet wormwood Artemisia annuaRat: a constituent raised digoxin AUC 2.34-fold and Cmax 1.81-fold, while the review states A. annua alone had no significant effect
Tea Camellia sinensisIn vitro P-glycoprotein inhibition; clinical study AUC fell from 8.20 to 5.44 ng*h/mL and Cmax from 2.47 to 1.76 ng/mL
Total Glucosides of Paeony (TGP) Paeonia lactifloraAcidic herb list: bioavailability decreased, contradicted elsewhere in the same review

Chemotherapy and oncology agents — 28 matched

Source: Fasinu PS, Rapp GK. Herbal Interaction With Chemotherapeutic Drugs - A Focus on Clinically Significant Findings. Front Oncol 2019;9:1356. doi:10.3389/fonc.2019.01356, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumDocetaxel, metastatic breast cancer, 600 mg twice daily for 12 days: clearance fell 36%, from 30.8 to 20.0 L/h/m2, which the review's own table calls non-statistically significant
Aloe veraNo clinical chemotherapy interaction data; strong potential based on laboratory results
Asian ginseng Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
Aspalathin Aspalathus linearisNo clinical chemotherapy interaction data; strong potential based on laboratory results
Dammarane sapogenins (from oriental ginseng) Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
EGCG Camellia sinensisNo clinically relevant interaction data, but strong potential for interactions based on laboratory results
EGCG and EGC (green tea) Camellia sinensisNo clinically relevant interaction data, but strong potential for interactions based on laboratory results
Field Mushroom Agaricus campestrisNo clinical chemotherapy interaction data; strong potential based on laboratory results
Garlic Allium sativumDocetaxel, metastatic breast cancer, 600 mg twice daily for 12 days: clearance fell 36%, from 30.8 to 20.0 L/h/m2, which the review's own table calls non-statistically significant
Ginsenoside Rb2 Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
Ginsenoside Rc Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
Ginsenoside Rg1 Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
Ginsenoside Rg3 Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
ginsenoside Rh Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
Golden root Rhodiola roseaNo clinical chemotherapy interaction data; strong potential based on laboratory results
Goldenseal Hydrastis canadensisNo clinical chemotherapy interaction data; strong potential based on laboratory results
Green tea polyphenols Camellia sinensisNo clinically relevant interaction data, but strong potential for interactions based on laboratory results
Matcha Camellia sinensisNo clinically relevant interaction data, but strong potential for interactions based on laboratory results
Milk Thistle Silybum marianumIrinotecan, 6 cancer patients, three times daily for 12 days: no significant pharmacokinetic change; clearance 31.2, 25.4 and 25.6 L/h across weeks
Panaxotriol Panax ginsengImatinib case report: hepatotoxicity after three months of a ginseng-containing energy drink, resolved on discontinuation; the multicomponent drink limits attribution
Purple coneflower Echinacea purpureaEtoposide case report: platelet nadir 16 x10^3/L with echinacea against 44 x10^3/L on etoposide alone. Separately, a prospective study in 10 cancer patients found no significant alteration in docetaxel pharmacokinetics
Rooibos (red tea) Aspalathus linearisNo clinical chemotherapy interaction data; strong potential based on laboratory results
Salidroside (Rhodiola) Rhodiola roseaNo clinical chemotherapy interaction data; strong potential based on laboratory results
Silibinin Silybum marianumIrinotecan, 6 cancer patients, three times daily for 12 days: no significant pharmacokinetic change; clearance 31.2, 25.4 and 25.6 L/h across weeks
St. John's wort Hypericum perforatumDocetaxel, 10 patients, 300 mg three times daily: AUC down 12%, clearance up 14%. Irinotecan crossover, 5 patients: SN-38 down 42%. Imatinib: AUC down 32% in one study, clearance up 43% in another
Tea Camellia sinensisNo clinically relevant interaction data, but strong potential for interactions based on laboratory results
Valerian Valeriana officinalisNo clinical chemotherapy interaction data; strong potential based on laboratory results
Wild Yam DioscoreaNo clinical chemotherapy interaction data; strong potential based on laboratory results

Anticoagulants and antiplatelets (Table 3, completed retrieval) — 34 matched

Source: Risks of Oral Anticoagulants: Interactions with Drugs and Medicinal Plants, Scientia Pharmaceutica 2025;93(3):35, mdpi.com/2218-0532/93/3/35 - Table 3 read in full on a completion pass, characters 100,000-128,599, retrieved 2026-11-14.

IngredientWhat the review reports
Allicin (Garlic extract) Allium sativumInhibits platelet aggregation; increased anticoagulation
Aloe veraReduces intestinal absorption or increases renal elimination; decreased anticoagulation
Anthocyanins Vaccinium myrtillus + Ribes nigrumAntiplatelet properties; increased anticoagulation
Bilberry Vaccinium myrtillusAntiplatelet properties; increased anticoagulation
Cranberry Vaccinium macrocarponAnthocyanins metabolized by CYP2C9 and CYP3A4; increased anticoagulation
Curcumin Curcuma longa L.Curcumin potentiates warfarin; increased anticoagulation
Dong quai Angelica sinensisNatural coumarins plus clot-inhibiting and antiarrhythmic effects; increased anticoagulation
EGCG Camellia sinensisVitamin K content counteracts warfarin; high doses reduce INR; decreased anticoagulation
EGCG and EGC (green tea) Camellia sinensisVitamin K content counteracts warfarin; high doses reduce INR; decreased anticoagulation
Garlic Allium sativumInhibits platelet aggregation; increased anticoagulation
Ginger Zingiber officinaleHas anticoagulant properties; increased anticoagulation
Glabridin Glycyrrhiza glabraInhibits CYP3A4; increased anticoagulation
Glycyrrhizin (Licorice) Glycyrrhiza glabraInhibits CYP3A4; increased anticoagulation
Goji berry Lycium barbarumInhibits CYP2C9; increased anticoagulation
Gotu kola Centella asiaticaInhibits CYP2C9 in vitro; increased anticoagulation
Green tea polyphenols Camellia sinensisVitamin K content counteracts warfarin; high doses reduce INR; decreased anticoagulation
Harpagophytum (Devil's Claw) Harpagophytum procumbensInhibits CYP2C8, CYP2C9, CYP2C19 and CYP3A4 in vitro; increased anticoagulation
Isoliquiritigenin Glycyrrhiza glabraInhibits CYP3A4; increased anticoagulation
Licorice Glycyrrhiza glabraInhibits CYP3A4; increased anticoagulation
Matcha Camellia sinensisVitamin K content counteracts warfarin; high doses reduce INR; decreased anticoagulation
Milk Thistle Silybum marianumInhibits CYP2C9; increased anticoagulation
Myrrh Commiphora myrrhaInduces liver enzymes; decreased anticoagulation
Panax quinquefolius (American ginseng) Panax quinquefoliusMechanism unclear; thought to speed warfarin metabolism through steroid-like ginsenoside effects; DECREASED anticoagulation. Note the species: this row is American ginseng, not Asian ginseng
Polyenylphosphatidylcholine (PPC) Glycine max phospholipid fractionThe review gives BOTH directions: CYP3A4 and CYP2C9 inhibition in vitro would raise the effect while vitamin K would lower it; its own effect column reads either increased or decreased
Purple coneflower Echinacea purpureaSpeeds warfarin breakdown; decreased anticoagulation
Red clover Trifolium pratenseInhibits CYP2C9 and contains coumarins; increased anticoagulation
Red sage Salvia miltiorrhizaBlood-thinning and vessel-widening properties that add to warfarin's action; increased anticoagulation
Saw palmetto Serenoa repensInhibits CYP2D6, CYP2C9 and CYP3A4; increased anticoagulation
Silibinin Silybum marianumInhibits CYP2C9; increased anticoagulation
Soy peptide fraction (hydrolyzed soy) Glycine maxThe review gives BOTH directions: CYP3A4 and CYP2C9 inhibition in vitro would raise the effect while vitamin K would lower it; its own effect column reads either increased or decreased
Soybean Glycine maxThe review gives BOTH directions: CYP3A4 and CYP2C9 inhibition in vitro would raise the effect while vitamin K would lower it; its own effect column reads either increased or decreased
St. John's wort Hypericum perforatumInduces CYP1A2, CYP2C9 and CYP3A4; decreased anticoagulation
Tea Camellia sinensisVitamin K content counteracts warfarin; high doses reduce INR; decreased anticoagulation
Turmeric Curcuma longaCurcumin potentiates warfarin; increased anticoagulation

Serotonergic drugs (Table 1, completed retrieval) — 18 matched

Source: Pharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22 - Table 1 read on a completion pass at characters 200,000-241,705, retrieved 2026-11-14.

IngredientWhat the review reports
Ashwagandha Withania somniferaModulates serotonin receptors and inhibits CYP3A4 and CYP2D6; with SSRIs and SNRIs; graded Low. A cited case reports serotonin syndrome with escitalopram
Asian ginseng Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
BerberineMAO-A inhibition, raises brain serotonin, and inhibits the CYP2D6 and CYP3A4 metabolism of SSRIs and SNRIs; with SSRIs, SNRIs, MAOIs and triptans; graded Low
Chinese goldthread Coptis chinensisNamed as the plant source behind the review's berberine MAO-A row, in a cited title on monoamine oxidase inhibitors from Coptis rhizome
Curcumin Curcuma longa L.Curcumin raises serotonin and dopamine release and inhibits MAO-A; with SSRIs and with fentanyl; graded Moderate
Dammarane sapogenins (from oriental ginseng) Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
Ginsenoside Rb2 Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
Ginsenoside Rc Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
Ginsenoside Rg1 Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
Ginsenoside Rg3 Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
ginsenoside Rh Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
Golden root Rhodiola roseaRaises serotonin and dopamine and inhibits CYP2C9, CYP2D6 and CYP3A4; with SSRIs, SNRIs and MAOIs; graded Low
L-TryptophanSerotonin precursor through 5-HTP, raising synthesis; with MAOIs, SSRIs, SNRIs and tricyclics; graded Moderate. A dietary amino acid, not a botanical
Panaxotriol Panax ginsengGinsenosides raise monoamine biosynthesis including serotonin; with SSRIs and SNRIs; graded Low. This botanical appears in BOTH the serotonergic and the arrhythmia table
Salidroside (Rhodiola) Rhodiola roseaRaises serotonin and dopamine and inhibits CYP2C9, CYP2D6 and CYP3A4; with SSRIs, SNRIs and MAOIs; graded Low
St. John's wort Hypericum perforatumThe ONLY row the review grades High: hyperforin inhibits serotonin, dopamine and noradrenaline reuptake; with SSRIs, SNRIs, triptans, MAOIs and buspirone
Turmeric Curcuma longaCurcumin raises serotonin and dopamine release and inhibits MAO-A; with SSRIs and with fentanyl; graded Moderate
Withanolides (Ashwagandha) Withania somniferaModulates serotonin receptors and inhibits CYP3A4 and CYP2D6; with SSRIs and SNRIs; graded Low. A cited case reports serotonin syndrome with escitalopram

Cardiac arrhythmia and QT (Table 2, completed retrieval) — 18 matched

Source: Pharmacoepidemiological Data on Drug-Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence, mdpi.com/2813-0618/4/4/22 - Table 2 read on a completion pass at characters 200,000-241,705, retrieved 2026-11-14.

IngredientWhat the review reports
Aloe veraIn laxative use, anthraquinone glycosides cause chronic hypokalemia and an arrhythmogenic substrate; with digoxin and diuretics. Shares one row with senna
Asian ginseng Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
BerberineQT prolongation, and inhibition of the CYP metabolism of antiarrhythmics; with QT-prolonging drugs, antiarrhythmics and quinolones
Bitter Orange Citrus aurantiump-Synephrine acts as an adrenergic agonist causing tachycardia and hypertension; with sympathomimetics and QT-prolonging drugs; QT itself not named in the row
Dammarane sapogenins (from oriental ginseng) Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
Evodia (Wu Zhu Yu) Evodia rutaecarpaEvodiamine, dehydroevodiamine and hortiamine inhibit hERG, prolonging the action potential and causing proarrhythmia; with antiarrhythmics
Ginsenoside Rb2 Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
Ginsenoside Rc Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
Ginsenoside Rg1 Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
Ginsenoside Rg3 Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
ginsenoside Rh Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
Glabridin Glycyrrhiza glabraInhibits 11-beta-HSD2, producing pseudo-hyperaldosteronism and hypokalemia that leads to torsades de pointes; with QT-prolonging drugs, diuretics and digoxin
Glycyrrhizin (Licorice) Glycyrrhiza glabraInhibits 11-beta-HSD2, producing pseudo-hyperaldosteronism and hypokalemia that leads to torsades de pointes; with QT-prolonging drugs, diuretics and digoxin
Guarana Paullinia cupanaShares one caffeine row with black tea, green coffee and yerba mate: adenosine receptor blockade raising sympathetic tone and calcium handling, causing tachycardia
Isoliquiritigenin Glycyrrhiza glabraInhibits 11-beta-HSD2, producing pseudo-hyperaldosteronism and hypokalemia that leads to torsades de pointes; with QT-prolonging drugs, diuretics and digoxin
Licorice Glycyrrhiza glabraInhibits 11-beta-HSD2, producing pseudo-hyperaldosteronism and hypokalemia that leads to torsades de pointes; with QT-prolonging drugs, diuretics and digoxin
Panaxotriol Panax ginsengGinsenosides, QT prolongation possibly through hERG; with QT-prolonging drugs, antiarrhythmics and quinolones. Appears in BOTH tables
Yerba mate Ilex paraguariensisShares the same caffeine row: adenosine receptor blockade, raised sympathetic tone, tachycardia. The four plants in that row carry one shared grade, not four

CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) — 27 matched

Source: Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review, Journal of the Chinese Medical Association 2026;89(8):578-592, doi 10.1097/JCMA.0000000000001404, PMC13524159 - all seven tables read on a completion pass. Tables 1 and 2 carry no botanicals (CYP families and CYP polymorphisms). Cell prose in this pass is close paraphrase of the source, not verbatim quotation; table captions, column headers, row counts, plant names, isoforms, directions and the figures shown in quotation marks are read from the page, retrieved 2026-11-14.

IngredientWhat the review reports
Astragalus Astragalus membranaceusTable 4 (as Huangqi): induces CYP3A4, evidence graded LOW, possible PXR activation. Tables 5 and 7 (as Astragalus) instead give weak competitive inhibition of CYP2C9 and CYP3A4 at VERY LOW risk from in vitro data. The source states both directions for the same plant under two names and does not reconcile them
Baicalein Scutellaria baicalensisTable 5 (as Huangqin): CYP2C9 inhibition and CYP2E1 induction, evidence MODERATE to HIGH, with NSAIDs, warfarin and phenytoin. Table 7 ranks it MODERATE to HIGH with losartan, warfarin and chlorzoxazone
Baicalin Scutellaria baicalensis GeorgiTable 5 (as Huangqin): CYP2C9 inhibition and CYP2E1 induction, evidence MODERATE to HIGH, with NSAIDs, warfarin and phenytoin. Table 7 ranks it MODERATE to HIGH with losartan, warfarin and chlorzoxazone
Baikal skullcap Scutellaria baicalensisTable 5 (as Huangqin): CYP2C9 inhibition and CYP2E1 induction, evidence MODERATE to HIGH, with NSAIDs, warfarin and phenytoin. Table 7 ranks it MODERATE to HIGH with losartan, warfarin and chlorzoxazone
Chinese magnolia vine Schisandra chinensisTable 5 (as Schisandra or Wuweizi): strong inhibition of CYP3A4 and P-glycoprotein, with tacrolimus levels reported to rise 6 to 13 fold in rats. Table 7 ranks it HIGH risk with very high toxicity and possible renal impairment
Common barberry Berberis vulgarisTable 6: inhibition of CYP2D6 and CYP3A4 via berberine, evidence graded HIGH from human liver microsomes and clinical trials
Cranberry Vaccinium macrocarponTable 3: inhibition of CYP2C9; stronger warfarin effect and higher bleeding risk
Curcumin Curcuma longa L.Table 7, MODERATE risk: inhibition of CYP3A, CYP1A1, CYP1A2 and CYP2B1, raising drug exposure. No interacting drug named in the row. Two reads of the page disagreed on whether the source states the binomial, so the species is carried from the catalog and not derived from this source
Deoxyschizandrin Schisandra chinensisTable 5 (as Schisandra or Wuweizi): strong inhibition of CYP3A4 and P-glycoprotein, with tacrolimus levels reported to rise 6 to 13 fold in rats. Table 7 ranks it HIGH risk with very high toxicity and possible renal impairment
Dong quai Angelica sinensisTable 7, LOW risk: mixed inhibition and induction across CYP1A2, CYP2D6, CYP2C9, CYP2E1 and CYP3A4, with clinical significance stated as uncertain
Epimedium (Horny Goat Weed) Epimedium koreanumTable 5: moderate CYP3A4 inhibition with IC50 reported as 121.9 micrograms per mL, evidence LOW, possible steroid level increases. Table 7 ranks it MODERATE risk and adds CYP2C19 and CYP2C9. The source does not name the Epimedium species
German chamomile Matricaria chamomillaTable 6: induction of CYP3A11 and CYP1A2 in mice, evidence HIGH to MODERATE from animal data; possible circadian disruption affecting drug clearance
Ginkgo bilobaTable 4: strongly induces CYP2C19 and CYP3A4, evidence graded STRONG from clinical data, nuclear receptor activation. Table 5 adds a CYP2C9 and anticoagulant interaction. Table 7 ranks it HIGH risk with omeprazole, clopidogrel and midazolam, therapeutic failure risk
Glycyrrhiza uralensis Fisch.Table 4 (as Gan Cao) states both directions in one row: mildly induces CYP3A4 and inhibits CYP1A2 and CYP2C, evidence LOW and explicitly in vitro only. Table 5 gives CYP2C9 inhibition at MODERATE evidence. Table 7 lists no CYP isoform for this herb at all, ranking it LOW and endocrine-only. The source does not reconcile these
Goji berry Lycium barbarumTable 3: inhibition of CYP3A4 and CYP2C9. Table 7 ranks it HIGH risk: CYP2C9 inhibition with warfarin plus CYP3A4 and CYP1A2 inhibition, high bleeding risk
GrapefruitTable 3: inhibition of intestinal CYP3A4; raises plasma levels of CYP3A4 substrates, statins and tacrolimus named
Green chiretta Andrographis paniculataTable 7 (as Chuanxinlian), MODERATE risk: induces CYP1A1 and inhibits CYP2B, CYP3A4 and CYP2C; bidirectional pharmacokinetic changes. No interacting drug named in the row
Ligusticum / Chuanxiong (Chuan Xiong) Conioselinum anthriscoidesTable 4 (as Chuanxiong): induces CYP1A2 and CYP3A4, evidence MODERATE from animal data, pathway unspecified. Table 7 ranks it LOW risk
Myrrh Commiphora myrrhaTable 6: CYP2C9 induction, evidence LOW to MODERATE from in vitro and in silico data; may raise clearance of warfarin-type substrates
Pomegranate Punica granatumTable 3: inhibition of CYP3A4 and CYP2C9; raises bioavailability of substrates, sildenafil and warfarin named
Punicalagin (from pomegranate extract) Punica granatumTable 3: inhibition of CYP3A4 and CYP2C9; raises bioavailability of substrates, sildenafil and warfarin named
Red sage Salvia miltiorrhizaTable 4 (as Danshen) states both directions in one row: induces CYP1A2, CYP2C9 and CYP3A4 and inhibits CYP1A2 and CYP2C, evidence MODERATE, tanshinones with possible PXR and AhR activation. Table 5 gives CYP2C9 and CYP3A4 inhibition with bleeding risk on warfarin. Table 7 ranks it HIGH risk against warfarin via CYP2C9 inhibition, qualified as possible. The source does not reconcile the directions
Rheum palmatum (rhein, a hydroxyanthraquinone) Rheum palmatum (rhein, a hydroxyanthraquinone)Table 7 (as Dahuang), MODERATE risk: CYP2D6 induction, possible reduced drug exposure. No interacting drug named in the row
Schisandrin B Schisandra chinensisTable 5 (as Schisandra or Wuweizi): strong inhibition of CYP3A4 and P-glycoprotein, with tacrolimus levels reported to rise 6 to 13 fold in rats. Table 7 ranks it HIGH risk with very high toxicity and possible renal impairment
St. John's wort Hypericum perforatumTable 3 and Table 5: strong CYP3A4 induction, graded high evidence. Table 7 ranks it HIGH risk for CYP3A4 and P-glycoprotein induction with tacrolimus, cyclosporine, ethinyl estradiol, midazolam, digoxin and imatinib
Turmeric Curcuma longaTable 7, MODERATE risk: inhibition of CYP3A, CYP1A1, CYP1A2 and CYP2B1, raising drug exposure. No interacting drug named in the row. Two reads of the page disagreed on whether the source states the binomial, so the species is carried from the catalog and not derived from this source
Wogonin Scutellaria baicalensisTable 5 (as Huangqin): CYP2C9 inhibition and CYP2E1 induction, evidence MODERATE to HIGH, with NSAIDs, warfarin and phenytoin. Table 7 ranks it MODERATE to HIGH with losartan, warfarin and chlorzoxazone

Which blends this reaches

61 of 68 blends contain at least one flagged ingredient. The number beside each is how many of its ingredients matched a drug class, not a measure of risk: a blend of a hundred botanicals has more chances to match than a blend of ten.

BlendFlagged ingredients
ACB — Cell-Cycle Checkpoint Restraint32
Force Field — Genomic Radioprotection30
Hormesis — Adaptive Stress Conditioning27
Trinity — Mind Body Spirit Harmonizer22
Anti-Fatigue — Cellular Energy Endurance21
Autonomous — Executive Command21
NRF2 Activator — Endogenous Antioxidant Induction19
EKG Cardioprotective — Contractile Reserve18
Spice — Anti-Inflammatory Polyphenol Powerhouse18
Lung Power — Respiratory Capacity17
Autophagy Activator — Cellular Self-Renewal16
NAD+ Booster — Cellular Energy Currency16
Victorious — Antiviral Immunity16
Fatty Liver Antidote — Hepatic Steatosis Reversal15
Helico — Gastric Colonization Defense15
Jing Force — Kidney Restoration15
ALZ — Memory Preservation14
Ascendance — Analgesic & Anti-Inflammatory13
Event Horizon — Post-Ethanol Restoration13
Glucose Blocker — Postprandial Control13
Holy Grail — Fat Leaves As Breath13
Obesogen Blocker — Endocrine Disruptor Defense13
Pancreas Regenerator — Islet Cell Restoration13
Peel — Flavonoid Powerhouse13
SIRT1 Activator — Caloric-Restriction Mimetic13
Adipocyte Apoptosis — Mature Fat Cell Clearance12
Ecstatic — Nervous System Stand-Down12
Female Fertility — Oocyte Competence12
Paraslayer — Intestinal Parasite Clearance12
Super Tonic Hair — Follicular Restoration12
Appetite Suppressant — Hunger Signal Control11
Ceramide Blocker — Lipotoxicity Neutralizer11
Lipolytic — Stored-Fat Mobilization11
Endurance Eternal — Pigment Preservation10
Male Fertility — Seminal Quality10
Niagra — Desire, Arousal & Climax10
Rewire — Total Brain Reset10
Senolytic — Senescent Zombie Cell Clearance10
Thermo — Thermogenic Disposal10
Triglyceride Decimator — Serum Lipid Reduction10
Ocular — Retinal & Macular Support9
Pulsar — Vascular Pressure Regulation9
Thrombolytic — Hemostatic Balance9
Plush — Collagen, Firmness & Glow8
Sabretooth — Periodontal Defense8
Thunder — Erectile Performance8
GLP-1 Activator — Endogenous Incretin Support7
Nebula — Warrior Mode Rocket Fuel7
Aegis — Myocardial Inflammatory Balance6
Gainz — Muscle, Strength & Recovery6
Hypnotic Sleep — Slow-Wave Architecture6
Titanium — Skeletal & Articular6
Heavy Metal Detox — Toxic Burden Excretion5
Liver Regenerator — Hepatic Restoration5
Purge — Intestinal Clearance5
Supernova — Daily Supertonic Reserve4
Anti-Adipogenic — Preadipocyte Arrest3
Galectin Inhibitor — Fibrotic Scar Tissue Restraint3
Spaceborn — Medicinal Mushroom Masterpiece2
B3AR Activator — Catecholamine Response Restored1
Interstellar Matcha — Ceremonial Grade1

7 blends carry none of the 126 flagged ingredients: Apigenin — Calming Senolytic, DHA — Algae Based Omega Guardian, Gynostemma — Herb of Immortality, Luteolin — Mast-Cell Restraint, Lactoferrin — The Miracle Molecule, Pine Pollen — Phyto-Androgen Complex, Shilajit — Destroyer of Weakness. That means none of their ingredients matched these 12 reviews, not that they are known to be free of interactions.

What this sweep did not reach

109 limits were recorded while the sweep ran, and they are printed here as recorded rather than summarized. Four of the 17 reviews were cut off by the retrieval limit before their tables ended, one evidence table refused retrieval altogether and is named rather than dropped, and two reviews contradict themselves on individual herbs — recorded here, not resolved.

ClassLimit, as recorded
Anticoagulants and antiplateletsTable 3 (possible plant-warfarin interactions) was truncated at 100,000 of 128,599 characters on the first pass. CLOSED: a completion pass read characters 100,000-128,599 and all 26 Table 3 rows sit in that remainder; they are published above. The per-row study identifiers behind Table 3's caption remain unenumerated.
Antidepressants, MAOIs and serotonergic drugsclinician.com evidence-based herb-drug table refused retrieval (client_error) — named, not omitted
Antidepressants, MAOIs and serotonergic drugsRetrieval was truncated at 100,000 of 241,705 characters on the first pass. CLOSED, and this was the worst of the cutoffs: characters 100,000-200,000 are reference list, and the article's OWN class-assignment tables sit at 200,000-241,705, so the original cutoff had severed them entirely. A completion pass read to the end of the article and recovered Table 1, published above as its own class.
Antidiabetic drugsRetrieval was truncated at 100,000 of 174,041 characters on the first pass. CLOSED: a completion pass read the remainder, which is reference list and back matter only and added no botanical. One gap remains open and is not closed by that pass - the article references a Table 1 that was not served at either offset, so any herb appearing only in Table 1 is unmeasured.
Antihypertensives and blood-pressure drugsRetrieval was truncated at 100,000 of 200,783 characters on the first pass. CLOSED: a completion pass read characters 100,000-200,783, which are the numbered reference list and site back matter with no review narrative and no table, and added no botanical.
Antihypertensives and blood-pressure drugshawthorn and pomegranate named in the introduction but their BP effects and interactions are not analyzed by the review, so they are NOT counted here
CYP450 enzymes and P-glycoproteinRetrieval was truncated at 100,000 of 158,743 characters on the first pass, and the note that later tables may name further herbs assumed those tables lay in the unread half. CLOSED - and it closed by disproving that assumption rather than by confirming it. A completion pass read characters 100,000-158,743 and found reference entries and back matter only, no table. A further pass then measured where the tables actually are: all SEVEN sit inside the article's first 100,000 characters, the range the first pass had already read. Tables 1 and 2 carry no botanicals at all, describing CYP families and clinically relevant CYP polymorphisms; Tables 3 to 7 carry 31 distinct plant entries across 41 rows, of which 27 match this catalog and are published above as their own class. No table appears after character 100,000 and none is served only as a separate table sub-page, so the three refusing sub-page channels were never the obstacle they appeared to be, and the guess that further herbs lay behind them is withdrawn. What remains is not a retrieval gap but a quotation limit, recorded separately: the one channel that served this article refused verbatim cell-by-cell transcription, so cell prose is close paraphrase, while captions, column headers, row counts, plant names, isoforms, directions, evidence grades and the figures shown in quotation marks are read from the page.
CYP450 enzymes and P-glycoproteinreview is internally inconsistent for Danshen and Gan Cao (induction vs inhibition stated differently in text and tables) — recorded, not resolved here
Cardiac drugs, arrhythmia and QT prolongationRetrieval was truncated at 100,000 of 241,705 characters on the first pass. CLOSED: the same completion pass recovered Table 2, the article's arrhythmia table, from characters 200,000-241,705, which the original cutoff had severed. It is published above as its own class and it names aconite, oleander, lily of the valley, kratom, yohimbe and evodia among others that the truncated pass could not see.
MSD Manual multi-class tablethe source table's own Chromium row links to the Chamomile page, an inconsistency in the source recorded here rather than resolved
Sedatives CNS depressants and benzodiazepinesthe review prints no herb count; the denominator 11 is the reviewer's own enumeration of the botanical genera it names, not a figure the review states
Sedatives CNS depressants and benzodiazepinesGROUP-LEVEL ATTRIBUTION, not herb-specific: the six caffeine-containing herbal drugs (tea, coffee, guarana, mate, cola, cocoa) share ONE table that does not break interactions down by herb, so those six rows carry the caffeine group finding and not a finding measured on the individual plant
Sedatives CNS depressants and benzodiazepinesevidence type is not labelled by the source for 10 of 11 botanicals; only hop is characterized, verbatim, as 'based mainly on experimental evidence'
Sedatives CNS depressants and benzodiazepinessource self-contradiction (valerian), recorded not resolved: the text states valerian 'does not affect the pharmacokinetics of caffeine, alprazolam, or midazolam to a clinically relevant extent' while its own table reports alprazolam plasma level up 19%
Sedatives CNS depressants and benzodiazepinessource self-contradiction (ginkgo), recorded not resolved: the text calls ginkgo a GABA-A antagonist while the table describes the same EGb 761 extract as a GABA-A agonist
Sedatives CNS depressants and benzodiazepinessource self-contradiction (hop), recorded not resolved: the section states no clinically significant interactions are reported in the EU herbal monograph while the hop table carries diazepam and phenobarbital rows reading additive effect, increased adverse reactions
Sedatives CNS depressants and benzodiazepinesdirection split within this class: valerian and hop POTENTIATE, while St John's wort, cannabis and the caffeine herbs REDUCE sedative effect; ginkgo is printed in both directions
Sedatives CNS depressants and benzodiazepinesanesthesia coverage is thin: only valerian carries general-anesthetic rows; ginkgo's surgical caution is about bleeding, not anesthetic interaction
Sedatives CNS depressants and benzodiazepinesprinted apparent typo reproduced as printed, not corrected: the caffeine hypnotics row gives the basis as CYP2C2, which is not a recognized CYP isoform
Sedatives CNS depressants and benzodiazepineskava and chamomile are not covered by this review at all; passionflower, lemon balm and lavender are named only as components of sedative tea combinations with no interactions analyzed
Sedatives CNS depressants and benzodiazepinesclinician.com and pmc.ncbi.nlm.nih.gov refused retrieval (reCAPTCHA interstitial) and were named rather than mined
Sedatives CNS depressants and benzodiazepinesa second source, Pharmaceuticals 2026;19(3):399 doi:10.3390/ph19030399, was opened but truncated at 100,000 of 250,301 characters and not fully mined; it adds Passiflora incarnata for this class, which is therefore NOT counted here
Thyroid medicationretrieval truncated at 100,000 of 157,173 characters on the first pass; a second pass read the remainder, so the whole article was covered
Thyroid medicationon the first pass the tables could not be read because they render as images; table rows were recovered on the second pass
Thyroid medicationsource self-contradiction (soy), recorded not resolved: one table reports no significant change in thyroid hormone levels while another states soy causes malabsorption by adsorbing levothyroxine
Thyroid medicationsource self-contradiction (coffee), recorded not resolved: two trials report comparable TSH whether coffee is taken 5 minutes or 1 hour after the dose, yet the same review cites those trials to advise delaying coffee by one hour
Thyroid medicationsource self-contradiction (papaya), recorded not resolved: the mechanism is given as unknown and a recommendation said to be impossible on the evidence, while the same row lists malabsorption and advises avoiding excessive intake
Thyroid medicationgap: a cited reference title names tea as a cause of levothyroxine malabsorption, but the review contains no tea row and gives no tea recommendation
Thyroid medicationSCOPE: this review covers levothyroxine only and addresses no antithyroid drug - methimazole, carbimazole and propylthiouracil are not covered
Thyroid medicationANTITHYROID DRUGS, honest empty: no published review enumerating botanical interactions with antithyroid drugs was found or opened; only consumer interaction databases surfaced, which are not published reviews and were not used
Thyroid medicationthe review states 63 studies were included but states no count of botanical items, so the denominator 16 is the reviewer's own enumeration
Thyroid medicationno binomials are stated by the source for these items and none were inferred
Thyroid medicationnon-botanical, recorded for completeness and excluded from the catalog match: vitamin C is reported to ENHANCE levothyroxine absorption, with the review recommending that concomitant ingestion be considered
Immunosuppressantsretrieval truncated at 100,000 of 134,114 characters on the first pass; a second pass read the remainder
ImmunosuppressantsSCOPE: this review covers TACROLIMUS only; cyclosporine, sirolimus, mycophenolate and transplant corticosteroids are not enumerated, so this class carries no botanical list for those agents
Immunosuppressantsno broader immunosuppressant review was opened: the candidates found sat on hosts not reachable this run, so nothing was extracted for cyclosporine, sirolimus, mycophenolate or corticosteroids
Immunosuppressantsthe review states no count of included articles and no count of herbs, so the denominator 13 is the reviewer's own enumeration
Immunosuppressantssource self-contradiction (green tea), recorded not resolved: catechins and theaflavins are listed as inhibiting CYPs and P-glycoprotein, which predicts higher exposure, while the same row gives the effect as inconclusive and the body reports a human rise alongside murine falls
Immunosuppressantssource self-contradiction (cranberry), recorded not resolved: the cited case reports a decrease while the review notes cranberry inhibits CYPs, which predicts the opposite
Immunosuppressantscontradiction recorded by the review itself (pomelo): one study contradicts the P-glycoprotein role
Immunosuppressantsgap (turmeric and ginger): elevation of tacrolimus is recorded for both with no active component and no mechanism, so the direction is asserted without explanation
Immunosuppressantstension recorded (Schisandra sphenanthera): exacerbation of tacrolimus toxicity and a protective effect on the liver appear in the same row
Immunosuppressantsreference-list only, backing no claim: Ginkgo biloba, garlic oil, milk thistle, black cohosh, goldenseal, kava kava, saw palmetto, Citrus aurantium and cannabidiol appear in the bibliography but are not discussed in the body
Statins and lipid-lowering drugssource self-contradiction (yarrow), recorded not resolved: the table lists yarrow as a P-glycoprotein inhibitor affecting atorvastatin while the discussion names yarrow among herbs that do not affect CYPs and may not interact significantly with statins
Statins and lipid-lowering drugssource self-contradiction (pepper-rosemary), recorded not resolved: the table lists it as a CYP3A4 inhibitor affecting three statins while the discussion's non-interacting list includes pepper/rosemary
Statins and lipid-lowering drugsNO HUMAN STATIN DATA IN THIS SOURCE: the article states its findings are preclinical and that the effect and severity of interactions are unknown when dealing with such preclinical findings; no effect sizes are given for any statin row
Statins and lipid-lowering drugsthe article states no count of herbal medicines, so the denominator 25 is the reviewer's own enumeration of species named in connection with statins
Statins and lipid-lowering drugsspelling defect in the source, reproduced as printed and not corrected: the article prints Achillea millefollium
Statins and lipid-lowering drugsno binomials are printed for the nine herbs named only as possibly non-interacting, so none were derived
Statins and lipid-lowering drugsSCOPE LIMIT: lipid-lowering drugs other than statins are absent from this source; it names no fibrate, fenofibrate or ezetimibe. Pravastatin is described as not metabolized and therefore less affected
Statins and lipid-lowering drugsa second, statin-dedicated source with human data was opened and named but NOT merged, because it enumerates polyphenol compounds rather than botanicals: Front Pharmacol 2025;16:1541871 doi:10.3389/fphar.2025.1541871. Its existence means the preclinical-only limitation is a property of the primary source, not of the literature
Statins and lipid-lowering drugsthe PDF was read from an institutional repository copy and could not be verified against the publisher's own record this run
Statins and lipid-lowering drugsfrontiersin.org refused direct retrieval through the egress proxy (403 connect_rejected) and was read through a different channel; one repository URL returned a fetch error and was abandoned without retry
Digoxin and cardiac glycosidesretrieval truncated at 100,000 of 168,248 characters on the first pass; a second pass read the remaining 68,248 characters, which contained only the end of the discussion, the conclusion and the reference list, so the article body is covered
Digoxin and cardiac glycosidesthe article states no herb count; its only stated count is that 49 articles were obtained, so the denominator 50 is the reviewer's own enumeration of distinct plant-derived entries
Digoxin and cardiac glycosidessource self-contradiction (ginkgo), verbatim: G. biloba has no effect on the pharmacokinetic parameters of digoxin, while G. biloba extract has a significant effect
Digoxin and cardiac glycosidessource self-contradiction (milk thistle): the results state it significantly induces P-glycoprotein mRNA and may decrease bioavailability, while the human study it cites found no significant change
Digoxin and cardiac glycosidessource self-contradiction (white peony): listed as acidic and therefore lowering bioavailability, yet a decoction containing it is said to promote digoxin absorption
Digoxin and cardiac glycosidessource self-contradiction (schisandra): listed as acidic and lowering bioavailability, while a tablet made from Schisandra sphenanthera extract is reported to raise digoxin plasma levels
Digoxin and cardiac glycosidessource self-contradiction (ginseng): the review says Panax ginseng enhances the effect of digoxin, while an injection containing it is said to decrease plasma concentration and a third study found no effect
Digoxin and cardiac glycosidescommon-name collision in the source, recorded not resolved: the same pinyin name is assigned to two species, Chaenomeles lagenaria and Carica papaya; both are carried as the review lists them
Digoxin and cardiac glycosidesnaming inconsistency in the source: Cyperus rotundus is given two different pinyin names in one article
Digoxin and cardiac glycosidessource nomenclature defect, recorded not resolved: the article pairs Areca catechu with the pinyin name for garlic; neither garlic nor Allium sativum appears anywhere in the article body, so this entry should not be read as either plant without an independent check
Digoxin and cardiac glycosidesincomplete identifiers in the source: the rose entry is genus-only, and no binomial is printed for wheat bran, belladonna, citrus peel, citrus juices, purple grape juice, green tea or St John's wort; none were derived
Digoxin and cardiac glycosidesChinese hawthorn is double-classified by the review, as lowering bioavailability and as antagonizing digoxin-induced arrhythmia; both directions are carried in one row
Digoxin and cardiac glycosidesseveral rows carry the review's own verdict that the effect on digoxin is not clear rather than a measured interaction: Dengdanhua, citrus juices, Cyperus rotundus, red sage, dong quai and ephedra
Digoxin and cardiac glycosidesnon-botanical items are deliberately excluded and named rather than omitted: oyster shell, toad secretion products, Calculus Bovis, mother-of-pearl injections, and a list of thirty calcium-containing medicines that are predominantly mineral or animal-derived
Chemotherapy and oncology agentsPODOPHYLLOTOXIN, the highest-stakes check for this catalog: the terms podophyllotoxin, Podophyllum and mayapple are ABSENT from the entire text of this review, including its abstract, body, tables and full reference list. This review therefore supports no claim whatever about podophyllotoxin with etoposide or any other oncology agent, in either direction
Chemotherapy and oncology agentsthe review's own counts, verbatim: 345 publications were retrieved and only 11 met the inclusion criteria; its abstract names six herbal products with human data
Chemotherapy and oncology agentsSCOPE LIMIT that caps the herb count by design: inclusion was limited to English-language studies performed in humans, so the short botanical list is a property of the inclusion criteria and is NOT evidence that other botanicals are safe with chemotherapy
Chemotherapy and oncology agentssource self-contradiction (milk thistle): the table says the irinotecan result is unlikely to cause clinical impact while the discussion says it can clinically influence chemotherapeutic pharmacokinetics
Chemotherapy and oncology agentssource self-contradiction (garlic): the table calls the docetaxel clearance decrease non-statistically significant while the text says it may pose significant risk of toxicity
Chemotherapy and oncology agentssource self-contradiction (St John's wort and docetaxel): the table reports a significant decrease in plasma docetaxel while the text says Cmax and half-life decreased non-significantly
Chemotherapy and oncology agentsspelling defect in the source, reproduced as printed: the table misspells Echinacea once
Chemotherapy and oncology agentsthe oncology drugs covered by human data are only etoposide, docetaxel, imatinib, irinotecan and nilotinib; no platinum agent, anthracycline, antimetabolite, vinca alkaloid, other taxane or immunotherapy agent carries human herb-interaction data in this review
Chemotherapy and oncology agentsgrapefruit juice is carried because the review groups it with herbal products, while itself noting it is mainly consumed non-medicinally
Chemotherapy and oncology agentsherbs mentioned only in non-chemotherapy contexts and therefore not carried: ginkgo, cranberry, grape seed, germander, black cohosh, licorice and betel nut
Chemotherapy and oncology agentsretrieval truncated at 100,000 of 144,094 characters on the first pass; a second pass read the remainder and added no new herb-plus-chemotherapy pairing
Chemotherapy and oncology agentsarticle-number ambiguity recorded not resolved: the DOI resolves to article 1356 while the page metadata field reads 500266
Chemotherapy and oncology agentsfrontiersin.org refused direct retrieval through the egress proxy (403 connect_rejected); the article was read through a different channel
Anticoagulants and antiplatelets (Table 3, completed retrieval)RETRIEVAL NOW COMPLETE for this source: the remainder, characters 100,000 to 128,599, was read on a completion pass and all 26 Table 3 rows sit in it. The earlier recorded blind spot - that Table 3 may name plants not captured - is closed, and those 26 plants are the ones it named.
Anticoagulants and antiplatelets (Table 3, completed retrieval)SPECIES DISCIPLINE: the ginseng row in this table is AMERICAN ginseng, Panax quinquefolius, and it runs in the DECREASED-anticoagulation direction. It is not Asian ginseng and must never be read as such.
Anticoagulants and antiplatelets (Table 3, completed retrieval)source self-contradiction, recorded not resolved: the remainder states that Table 3 is the only place plants appear, yet the earlier portion names valerian in body prose, and valerian never reaches Table 3
Anticoagulants and antiplatelets (Table 3, completed retrieval)source spelling defect, reproduced as printed and not corrected: Danshen's binomial is printed Salvia milthiorriza in Table 3 and Salvia miltiorrhiza in the body text
Anticoagulants and antiplatelets (Table 3, completed retrieval)source self-contradiction, recorded not resolved: soy is given both directions by the review itself
Anticoagulants and antiplatelets (Table 3, completed retrieval)the per-row underlying study identifiers are UNREACHED: Table 3's caption cites its sources but those citations were not enumerated, so no row here carries its own primary identifier
Serotonergic drugs (Table 1, completed retrieval)RETRIEVAL NOW COMPLETE for this source. The first pass stopped at 100,000 characters, and characters 100,000-200,000 turned out to be reference list only. The article's OWN class-assignment tables sit at 200,000-241,705, so the original cutoff had severed them entirely. A completion pass read to the end and recovered them; that is where every row above and in the arrhythmia class comes from.
Serotonergic drugs (Table 1, completed retrieval)UNSUPPORTED ROW, recorded not resolved: the review assigns ginkgo a serotonergic mechanism, but every ginkgo reference it cites is titled about seizures or general toxicity, including one on fatal seizures. No serotonin source backs that row.
Serotonergic drugs (Table 1, completed retrieval)the review's own grading footnote contradicts its cells: it defines Low as Level 5 and Grade D, yet six rows are printed as level 4 with grade D; it ties Grade C to Moderate, yet St John's wort is printed High with grade C; and ginkgo is printed with a grade E that the footnote never defines
Serotonergic drugs (Table 1, completed retrieval)the footnote is also internally overlapping: it assigns Level 5 to both the Low and the Moderate band, so the two cannot be told apart
Serotonergic drugs (Table 1, completed retrieval)cross-table contradiction: berberine is Low in the serotonergic table and Moderate in the arrhythmia table at the identical level and grade, and ginseng carries the same word at two different levels
Serotonergic drugs (Table 1, completed retrieval)the table carries no active-constituents column, and it lists an opioid among turmeric's co-interactants inside a serotonergic table
Serotonergic drugs (Table 1, completed retrieval)the retrieval tool enforced a 125-character ceiling on verbatim quotation, so these rows are faithful reconstructions of the table cells rather than byte-exact cell text
Cardiac arrhythmia and QT (Table 2, completed retrieval)RETRIEVAL NOW COMPLETE for this source: the original 100,000-character cutoff had severed Tables 1 to 3, which sit at 200,000-241,705 and carry the article's actual class assignments. A completion pass read to the end of the article.
Cardiac arrhythmia and QT (Table 2, completed retrieval)BUNDLED ROWS, stated rather than hidden: ephedra with sida, aloe with senna, and guarana with black tea, green coffee and yerba mate are each a SINGLE table row carrying one shared grade. They are split into separate botanical rows here and are not independently graded by the article.
Cardiac arrhythmia and QT (Table 2, completed retrieval)QT IS NOT NAMED for five of these rows - ephedra and sida, bitter orange, yohimbe, the caffeine row and evodia. They sit in the arrhythmia table on adrenergic or ion-channel grounds instead. Only licorice, kratom, berberine, ginseng and evodia carry explicit QT or repolarization wording.
Cardiac arrhythmia and QT (Table 2, completed retrieval)contradiction across the sources the review itself cites, on ephedra: one cited title reports that an ephedrine-alkaloid-free extract has no arrhythmia effect, while two others report adverse cardiovascular events with ephedra alkaloids. The review nonetheless grades ephedra High. Recorded, not resolved.
Cardiac arrhythmia and QT (Table 2, completed retrieval)a second binomial is printed for the oleander row in a cited title, and a separate cited title names yellow oleander, which is a different taxon and is NOT carried as a row here
Cardiac arrhythmia and QT (Table 2, completed retrieval)cross-class drug listing: the arrhythmia table names SSRIs among kratom's interacting drugs
Cardiac arrhythmia and QT (Table 2, completed retrieval)the review's grading footnote contradicts its own cells here too, tying Grade D to Low while printing Moderate rows at grade D, and tying Grade C to Moderate while printing Moderate rows at level 3
Cardiac arrhythmia and QT (Table 2, completed retrieval)the retrieval tool enforced a 125-character ceiling on verbatim quotation, so these rows are faithful reconstructions of the table cells rather than byte-exact cell text
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)The CYP450 retrieval that this file completes is CLOSED, and it closed by disproving its own premise. All seven tables of this review sit inside the first 100,000 characters of the article, the range an earlier pass had already read. No table appears after that point and no table is served only as a separate sub-page, so the earlier note that later tables might name further plants was a guess and is now withdrawn. Tables 1 and 2 carry no botanicals at all: they describe CYP families and clinically relevant CYP polymorphisms
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)Cell prose in this pass is close paraphrase, not verbatim quotation. The working channel's reader twice refused full cell-by-cell transcription, citing a 125-character limit on quoted source text. Table captions, column headers, row counts, plant names, isoforms, directions, evidence grades and the figures carried in quotation marks are read from the page; the remaining cell wording is paraphrase and is not presented here as quotation. Anything to be published as a direct quotation from these tables must be re-opened against the source
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)ASTRAGALUS MEMBRANACEUS is a third internal contradiction in this review, beyond the two already recorded, and the dual naming partly masks it: Table 4 calls the plant Huangqi and gives CYP3A4 INDUCTION by PXR activation, while Tables 5 and 7 call it Astragalus and give competitive INHIBITION of CYP2C9 and CYP3A4. The directions are opposed for the same isoforms in the same review and the source does not reconcile them
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)ASHWAGANDHA, Withania somnifera, is deliberately NOT flagged for this class. Table 6 of this review records no significant inhibition, with IC50 greater than 100 micrograms per mL and evidence graded MODERATE, and calls the interaction risk low. Flagging the plant on the strength of a row that reports an absence would overstate the record. It remains flagged under the serotonergic and MSD classes on their own sources. This also places two published reviews in disagreement: the serotonin and arrhythmia review states that ashwagandha inhibits CYP3A4 and CYP2D6, while this review reports no significant inhibition. Both readings are recorded and neither is resolved here
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)Four plants that this review discusses in PROSE appear in none of its seven tables: ginseng, Panax ginseng, for CYP3A4 and CYP2D6; He Shou Wu, Polygonum multiflorum, for CYP1A2, CYP2E1 and CYP3A4; milk thistle, Silybum marianum, for mild CYP3A4 inhibition; and garlic oil for CYP2E1. A table-only reading of this review therefore under-counts it. All four were already captured by the earlier pass on this same article and are already flagged
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)The drug column of Table 7 is sparse: 13 of its 22 rows name no interacting drug, and one row gives the drug only as the unexpanded abbreviation TP. Table 7 also carries no dedicated CYP column, so the isoforms recorded here for that table are read from each row's own text
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)Binomials this review does not state are left empty rather than derived: the species of Epimedium, of Coptidis Rhizoma and of Leonurus, and binomials for cruciferous vegetables. Glycyrrhiza is Glycyrrhiza uralensis in Table 7 but Glycyrrhiza spp. in the prose, so only the exact species named in the table is matched here and the Glycyrrhiza glabra entries in the catalog are not flagged on this source
CYP450 and P-glycoprotein (Tables 1-7, completed retrieval)Three channels refused this article and were not retried: a direct request to the article page returned a proxy 403; the publisher's own copy by DOI resolver failed at its site; and a mirror at semanticscholar.org was disallowed by robots. The table sub-pages were not probed because that same channel had already served a captcha. One channel served the article, and every reading above comes from it

Three further drug classes named as a concern in the Limits Register — sedatives and CNS depressants, thyroid medication and immunosuppressants — are covered here only where the MSD Manual table or one of the other six reviews happens to name a botanical for them. They have had no review of their own in this sweep, and statins, digoxin and chemotherapy agents have had none either. Anyone taking any of these should put the full ingredient list in front of a prescriber rather than read an absence here as clearance.

The depth pass — what the human record says for the 4 most-carried of them

A literature match is a flag, not a finding. For the flagged ingredients carried in the most blends, the primary sources were read and are set out here: what was measured, at what exposure, and in what kind of study. The study that looked and found nothing is given the same prominence as the one that found something, because a register that printed only the positive half would not be worth reading.

Asian ginseng Panax ginseng — carried in 25 blends

What the human record shows

FindingExposure, design and source
Induced CYP3A: midazolam AUC geometric mean ratio 0.66 (95% CI 0.55-0.78), Cmax 0.74, half-life 0.71. Fexofenadine pharmacokinetics unaltered, so no P-glycoprotein effect.500 mg twice daily for 28 days; standardization not stated. Probes midazolam 8 mg and fexofenadine 120 mg.
Open-label single-sequence pharmacokinetic trial, 12 healthy participants
J Clin Pharmacol 2012;52(6):932-939. doi:10.1177/0091270011407194
Hepatotoxicity on long-stable imatinib after ginseng was added: ALT 1069 U/L, AST 481 U/L, biopsy showed acute lobular hepatitis. Imatinib was later restarted at the same dose with no recurrence.Daily ginseng in energy drinks for 3 months, dose not stated, on imatinib 400 mg daily taken for 7 years without prior complication.
Single case report, 26-year-old man; causality rated probable on two scales
Ann Pharmacother 2010;44(5):926-8. PMID 20332334
Korean red ginseng added to mFOLFOX-6 chemotherapy: grade 3 or higher neutropenia 13% against 7% on placebo. The regulatory assessor concluded an interaction could not be established and the authors could not explain the difference.2000 mg/day for 16 weeks; extract ratio and solvent not reported, which the assessor cites as the reason the interaction cannot be established.
Randomized placebo-controlled trial in colorectal cancer patients, 219 per arm
EMA/HMPC assessment report on Panax ginseng radix, revision 1, section 5.5.4

What looked and found nothing

FindingExposure, design and source
No significant change in warfarin pharmacokinetics or effect. S-warfarin AUC ratio 0.89 (90% CI 0.82-0.98), R-warfarin 0.91, INR AUC ratio 1.01, platelet aggregation 1.0.Capsules each equivalent to 0.5 g root and 8.93 mg ginsenosides, two capsules three times daily, 7 days before and after a single 25 mg warfarin dose.
Open-label randomized three-way crossover, 12 healthy men
Br J Clin Pharmacol 2004;57(5):592-599. doi:10.1111/j.1365-2125.2003.02051.x
No significant change in mean INR and no enhanced anticoagulation in patients already on stable warfarin.Korean red ginseng extract 1 g for 6 weeks, crossover with a 3-week washout against placebo.
Crossover placebo-controlled study, 31 patients with valve replacement
EMA/HMPC assessment report on Panax ginseng radix, revision 1, section 5.5.4
Directly contrary to the CYP3A induction finding above: probe ratios for CYP2C9, CYP3A4 and OATP1B1 all stayed inside the 0.8-1.25 no-interaction bounds.Red ginseng extract, single and multiple doses over 15 days; dose not stated in the record opened.
Probe-cocktail study, 15 men
EMA/HMPC assessment report on Panax ginseng radix, revision 1, section 5.5.4

Limits on this row

Berberine — carried in 29 blends

What the human record shows

FindingExposure, design and source
Markedly raised cyclosporine exposure in transplant patients: trough up 88.3%, AUC up 34.5%, oral clearance down 40.4%, all P<0.05.0.2 g three times daily for 12 days alongside cyclosporine 3 mg/kg twice daily. Preparation, salt and standardization not stated.
Pharmacokinetic study in 6 renal transplant recipients, each on cyclosporine alone then with berberine
Eur J Clin Pharmacol 2005;61(8):567-572. doi:10.1007/s00228-005-0952-3
The same study's controlled arm: after 3 months the berberine group still had cyclosporine troughs 29.3% higher and concentration-to-dose ratios 27.8% higher than the berberine-free group, P<0.05.0.2 g three times daily for 3 months.
Randomized controlled trial, 52 on cyclosporine plus berberine against 52 on cyclosporine alone
Eur J Clin Pharmacol 2005;61(8):567-572. doi:10.1007/s00228-005-0952-3
Repeated berberine decreased CYP2D6, CYP2C9 and CYP3A4 activity: the dextromethorphan ratio rose ninefold and the losartan ratio doubled, both P<0.01, and midazolam AUC rose 40%, P<0.01.300 mg three times daily for 2 weeks against a placebo period, with a five-probe cocktail.
Two-phase randomized crossover in healthy male subjects; sample size not stated on the record opened
Eur J Clin Pharmacol 2012;68:213-217. doi:10.1007/s00228-011-1108-2

What looked and found nothing

FindingExposure, design and source
Inside the same cocktail that found three positives, CYP2C19 and CYP1A2 showed no statistically significant difference from placebo.300 mg three times daily for 2 weeks; omeprazole and caffeine probes.
Two-phase randomized crossover; sample size not stated
Eur J Clin Pharmacol 2012;68:213-217. doi:10.1007/s00228-011-1108-2
No significant effect on liver or renal function with berberine alongside cyclosporine.0.2 g three times daily for 3 months.
Randomized controlled trial, 52 against 52
Eur J Clin Pharmacol 2005;61(8):567-572. doi:10.1007/s00228-005-0952-3

Limits on this row

Ashwagandha Withania somnifera — carried in 23 blends

What the human record shows

FindingExposure, design and source
A pharmacodynamic basis for a thyroid-drug interaction, measured without any co-administered drug: ashwagandha significantly changed thyroid hormones against placebo in subclinical hypothyroidism, TSH P<0.001, T3 P=0.0031, T4 P=0.0096.Root extract 600 mg daily for 8 weeks against starch placebo; standardization not stated. Baseline TSH 4.5-10 microIU/L.
Randomized double-blind placebo-controlled pilot study, 50 participants
J Altern Complement Med. doi:10.1089/acm.2017.0183
Hepatotoxicity case series, five patients, all jaundiced: peak ALT 261-580 U/L and bilirubin 5.9-14.4 mg/dL, one biopsy showing acute cholestatic hepatitis. Chemical analysis confirmed ashwagandha in the products with no other toxic compound identified.450-1350 mg/day by label information; latency 5 to 116 days.
Case series of 5, causality by structured expert opinion: one definite, two highly likely, one probable, one possible
Liver Int 2020;40(4):825-829. doi:10.1111/liv.14393. PMID 31991029
A suppressed-TSH presentation with supraventricular tachycardia at 173 bpm, though free T4 and total T3 were both within range. This was a SUBSTITUTION, not co-administration: the patient had stopped levothyroxine about two years earlier.Root extract tablets for about two years; dose, product and formulation not stated.
Single case report, 73-year-old woman with Hashimoto thyroiditis
Cureus 2022;14(3):e23494. doi:10.7759/cureus.23494

What looked and found nothing

FindingExposure, design and source
No significant change or abnormality in haematology, serum biochemistry including hepatotoxicity evaluation, or thyroid hormones - the exact endpoints the two concerns above rest on. No participant in either group reported an adverse event.Root extract 300 mg twice daily for 8 weeks against matching placebo; standardization not stated.
Randomized double-blind placebo-controlled parallel-group study, 80 healthy adults
Complement Ther Med 2021;57:102642
Laboratory, not a human exposure: CYP inhibition concentrations of 161.9 to 528.1 micrograms per mL, all above the authors' own no-inhibition threshold. The authors state these results do not establish clinical safety.In pooled human liver microsomes across seven concentrations. No human subjects.
In vitro reversible CYP inhibition assay
Front Pharmacol 2022;13:973768. doi:10.3389/fphar.2022.973768

Limits on this row

Golden root Rhodiola rosea — carried in 17 blends

What the human record shows

FindingExposure, design and source
Modestly inhibited CYP2C9 in people: the losartan metabolite ratio fell 21%, P=0.023, the effect stronger in extensive metabolizers.A commercial 290 mg Rhodiola extract, 14 days of pretreatment, with a five-probe cocktail measured 4 hours after intake.
Randomized two-phase crossover probe-cocktail study, 13 healthy volunteers
Eur J Clin Pharmacol 2016;72:295-300
A vegetative syndrome with restlessness and trembling after 15 days, interpreted by the authors as serotonergic. Note the DIRECTION: the authors excluded a pharmacokinetic interaction in the Rhodiola-to-drug direction and proposed the reverse, paroxetine raising Rhodiola exposure.Paroxetine 20 mg/day plus about 400 mg/day of a Rhodiola product, for 15 days, patient self-initiated.
Single case report, 68-year-old woman
Neuropsychiatrie 2015;29:36-38. doi:10.1007/s40211-014-0124-8
Pharmacovigilance accumulation, mostly with psychotropics: co-use reports with sertraline, paroxetine, duloxetine, amitriptyline and etanercept, plus a 147-case combination series. The assessor notes reports involving multiple concomitant drugs cannot be attributed to Rhodiola.No doses are given for any of these reports.
Spontaneous adverse-event reports and a combination case series
EMA/HMPC assessment report on Rhodiola rosea, revision 1, section 5.5.4

What looked and found nothing

FindingExposure, design and source
No significant effect on CYP1A2, CYP2C19, CYP2D6 or CYP3A4 - four of the five enzymes in the same human cocktail that found the CYP2C9 change.The same 290 mg extract for 14 days.
Randomized two-phase crossover probe-cocktail study, 13 healthy volunteers
Eur J Clin Pharmacol 2016;72:295-300
Regulatory conclusion: no clinically relevant interactions have been observed, and the assessor records that the clinical relevance of the 21% CYP2C9 change is unclear.Applies to the traditional-use preparations the monograph covers.
Regulatory assessment of the whole published and pharmacovigilance record
EMA/HMPC assessment report on Rhodiola rosea, revision 1
Animal, not human: a rat study found no significant change in warfarin or theophylline pharmacokinetics, while a rabbit study found an almost two-fold increase in losartan exposure.Doses and preparations not stated in the section opened. Non-human throughout.
Rat and rabbit pharmacokinetic studies
EMA/HMPC assessment report on Rhodiola rosea, revision 1, section 3.2

Limits on this row

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.